University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2018

Rebound Relationships: An Investigation Of Hiv-1 Rebound
Dynamics And Host Immune Responses During Analytical
Treatment Interruption
Danielle Brenda Salantes
University of Pennsylvania, dsalantes@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Genetics Commons, Immunology and Infectious
Disease Commons, Medical Immunology Commons, and the Virology Commons

Recommended Citation
Salantes, Danielle Brenda, "Rebound Relationships: An Investigation Of Hiv-1 Rebound Dynamics And
Host Immune Responses During Analytical Treatment Interruption" (2018). Publicly Accessible Penn
Dissertations. 3179.
https://repository.upenn.edu/edissertations/3179

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3179
For more information, please contact repository@pobox.upenn.edu.

Rebound Relationships: An Investigation Of Hiv-1 Rebound Dynamics And Host
Immune Responses During Analytical Treatment Interruption
Abstract
In HIV-infected patients, combination antiretroviral therapy (cART) during HIV-1 infection potently
suppresses viral replication and slows progression to AIDS. Upon cessation of cART, however, systemic
infection is rapidly re-established due to the long-lived pool of latently infected cells, or HIV reservoir, that
is seeded early in infection and persists despite years of cART in patients. This long-lived reservoir is the
target of novel curative strategies. In order to determine in vivo efficacy of these interventions, closely
monitored analytical treatment interruption (ATI) is required. Previously conducted ATI trials have
provided important baseline information regarding the kinetics and diversity of viruses emerging from
latency. As future HIV curative clinical trials move towards prolonged periods of ATI, studies assessing
the effect of ATI on host virus-immune dynamics will provide an important baseline that will further our
understanding of trial outcomes. In this thesis, I conducted single genome sequencing (SGS) of HIV-1 env
and neutralization assays using autologous antibodies to characterize the viral and immune dynamics of
rebound in two clinical trials: a longitudinal ATI study in the absence of any intervention, and a brief ATI
study involving administration of the broadly neutralizing antibody VRC01. Our data, consistent with
previous studies, demonstrated that viral rebound occurs within four weeks of ATI and is established by
multiple latently infected cells in the majority of HIV-infected participants. Analyses of plasma containing
VRC01 and/or autologous antibodies show that latent reservoir viruses can experience an antibodymediated neutralization sieve effect, thus preventing the persistence of antibody-sensitive viruses.
Additionally, SGS of latent viruses before and after brief ATI show that the size and composition of the
peripheral latent viral reservoir is not significantly altered during ATI, demonstrating that short-term ATI is
safe. Taken together, these data highlight the complex virus-host dynamics during ATI, and further
suggest that passively infused or host-derived neutralizing antibodies can exert selective pressure,
altering the evolution of HIV in its host.
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ABSTRACT

REBOUND RELATIONSHIPS: AN INVESTIGATION OF HIV-1 REBOUND DYNAMICS
AND HOST IMMUNE RESPONSES DURING ANALYTICAL TREATMENT
INTERRUPTION
D. Brenda Salantes
Katharine J. Bar, M.D.

In HIV-infected patients, combination antiretroviral therapy (cART) during HIV-1 infection
potently suppresses viral replication and slows progression to AIDS. Upon cessation of
cART, however, systemic infection is rapidly re-established due to the long-lived pool of
latently infected cells, or HIV reservoir, that is seeded early in infection and persists
despite years of cART in patients. This long-lived reservoir is the target of novel curative
strategies.

In order to determine in vivo efficacy of these interventions, closely

monitored analytical treatment interruption (ATI) is required. Previously conducted ATI
trials have provided important baseline information regarding the kinetics and diversity of
viruses emerging from latency. As future HIV curative clinical trials move towards
prolonged periods of ATI, studies assessing the effect of ATI on host virus-immune
dynamics will provide an important baseline that will further our understanding of trial
outcomes. In this thesis, I conducted single genome sequencing (SGS) of HIV-1 env
and neutralization assays using autologous antibodies to characterize the viral and
immune dynamics of rebound in two clinical trials: a longitudinal ATI study in the
absence of any intervention, and a brief ATI study involving administration of the broadly
neutralizing antibody VRC01. Our data, consistent with previous studies, demonstrated
that viral rebound occurs within four weeks of ATI and is established by multiple latently
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infected cells in the majority of HIV-infected participants. Analyses of plasma containing
VRC01 and/or autologous antibodies show that latent reservoir viruses can experience
an antibody-mediated neutralization sieve effect, thus preventing the persistence of
antibody-sensitive viruses. Additionally, SGS of latent viruses before and after brief ATI
show that the size and composition of the peripheral latent viral reservoir is not
significantly altered during ATI, demonstrating that short-term ATI is safe. Taken
together, these data highlight the complex virus-host dynamics during ATI, and further
suggest that passively infused or host-derived neutralizing antibodies can exert selective
pressure, altering the evolution of HIV in its host.
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CHAPTER 1
Introduction
Epidemiology of HIV-1
In 1983, human immunodeficiency virus (HIV-1) was discovered as the causative agent
of Acquired Immunodeficiency Disease (AIDS) and remains a global health concern with
no vaccine and over 60 million infected and 35 million deaths from AIDS-related
illnesses1,2,3,4. Early genome sequencing and in vitro viral isolation characterized HIV as
a retrovirus with two related types: HIV-1 and HIV-2. HIV-1 leads the majority of human
infections globally while HIV-2 is isolated primarily in West African countries5.
Phylogenetic analyses identified simian immunodeficiency viruses (SIVs) as the closest
relative of HIV and determined that the epidemic arose through multiple independent
cross-species

transmission

events

between humans

and SIV-infected

African

primates5,6. HIV-1 strains can be categorized into four distinct phylogenetic groups: M, N,
O and P, where group M viruses are the principal cause of the AIDS pandemic with an
estimated index transmission event occurring between 1910-19307,8. Further modeling of
the most recent common ancestor of HIV-1 Group M viruses identified nine clades (A, B,
C, D, F, G, H, J, K), with clade B viruses representing the most common subtype
responsible for HIV-1 infection in North America and Europe. In 2017, 37 million people
were living with HIV-1 and 1.8 million new people are estimated to have been newly
infected this year. Due to the prevalence of Clade B viruses in North America and the
focus of clinical trials performed in this region in this thesis, I will primarily highlight clade
B infection in human subjects who have previously participated in curative HIV-1 clinical
trials.
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HIV-1 biology and genetic diversity
HIV-1 is an enveloped virus of the family Retroviridae, and genus, lentivirus, which is
derived from the Latin word lentus, or slow, indicative of its long incubation periods and
persistent viral replication9.

The genome of HIV-1 is a coding RNA with nine open

reading frames that produce 15 proteins and is approximately 9.8 kilobases in length10.
Centrally located genes encode three protein classes: 1. Structural proteins: Gag, Pol,
and Env; 2. Regulatory proteins: Tat and Rev; and 3. Accessory proteins: Vpu, Vpr, Vif,
and Nef. The 160 kilodalton protein, env, mediates viral fusion into host cells and is a
critical component of viral immune evasion11. The host protease, Furin, cleaves gp160
into gp41 (transmembrane of env) and gp120 (located on surface of the infected cell or
virion), which are arranged as a multimer or trimer in their active state10. Escape
mutations within env rapidly spread throughout the viral population during chronic
infection, and is driven by strong selection pressure imposed by cytotoxic CD8+ T cells
and neutralizing antibodies12.

In this thesis, I will primarily focus on neutralizing

antibodies as the drivers of HIV-1 Env genetic diversity during viral rebound. HIV-1 has
a propensity to infect activated CD4+ T cells through engagement of gp120 to the cell
surface receptor, CD4, and upregulated co-receptor proteins (CCR5, CXCR4).
Engagement of these receptors triggers conformational change in the env glycoprotein
which mediate fusion of the virus into the host cytoplasm. Transcription of the viral
genome is then initiated through HIV-1 Reverse Transcriptase (RT), which converts
single stranded RNA into a double stranded DNA genome called a provirus. Within
hours, the provirus is then trafficked into the nucleus where it is integrated into host
DNA13,14.
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One hallmark feature of HIV-1 among all retroviruses is its extensive genetic diversity.
This diversity can be attributed to its rapid turnover rate15,16 in combination with a high
mutation rate guided by an error-prone RT17. Mathematical modeling takes both
variables into account and estimates that the total HIV-1 production rate is 10.3 virions
per day with a nucleotide substitution rate of approximately 2x10-5 mutations/base
pair/cycle15,16,18,19. This rapid increase in diversity allows HIV-1 virions to quickly escape
mounting host immune pressures during viral replication, as well as pressure from
monotherapy from a single antiretroviral agent. As such, successful viral suppression
requires a multi-pronged approach with a combination of potent antiretrovirals (cART)
targeting various stages of HIV-1 replication at once.

HIV-1 transmission and pathogenesis
HIV-1 transmission in humans most commonly occurs through contact with viruses at
mucosal surfaces or from percutaneous inoculation20,21. The period between infection of
the first host cell to when virus is detectable in the plasma is called the eclipse phase
and is estimated to be approximately 7-21 days22–26. Fiebig et al. described 6 sequential
stages of acute viremia

27

. In Fiebig I, only HIV-1 RNA can be detected in the blood.

Within 7 days, the viral core protein p24 can be detected in Fiebig II as the HIV viral load
rises above 10,000 copies/ml and increases at approximately 0.35 log10HIV RNA per
day. Peak viral loads, rapid decline of CD4+ T cells, and virus-specific anti-gp41 IgM
antibodies can be detected in Fiebig III. During peak viremia, some infected individuals
experience symptoms of acute retroviral syndrome, including fever, rash, severe fatigue,
diarrhea, and myalgias. Following the acute stages of infection, there is a precipitous
depletion of susceptible CD4+ T cell targets and generation of partially-effective host
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immune responses, leading to progression of Fiebig stages IV-VI. These stages include
a 2-log decrease in plasma vRNA from peak viremia, and the establishment of the
plasma viral setpoint28. Anti-HIV antibodies are also generated at this time, though these
antibodies are non-neutralizing and do not mediate antibody-dependent cell-mediated
virus inhibition (ADCVI). Neutralizing antibodies that target the variable region of env
generally appear within 12 weeks of infection in clade B-infected individuals29–32. The
progression to clinical symptoms can vary among individuals, but often occurs slowly.
Until this period, infected individuals are asymptomatic and considered to be chronically
infected as viral set point is maintained with large numbers of CD4+ T cells becoming
infected and dying each day33,34. AIDS is clinically defined when CD4+ T cell counts are
less than 200mm3 35–37, leading to the establishment of opportunistic infections.

Sequence analysis of viruses from homosexual, heterosexual, mother-to-child or
percutaneous transmission pairs have determined that productive infection typically
occurs with one or a few transmitted/founder (T/F) variants that rapidly evolve over the
course of infection38–40. In addition, transmission pair analyses have determined that
despite increased genetic diversity within the pair donor, the majority (76%) of pair
recipients established productive clinical infection through a single virus or virus infected
cell, while the minority of recipients (24%) had evidence of infection by at least two to
five viruses. This low multiplicity of infection and limited viral evolution preceding peak
viremia suggests a mucosal bottleneck occurs during initial infection preventing multiple
transmission events from a pool of diverse viruses from the chronically infected
donor41,42,43.
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Dynamics of the autologous antibody response during infection
Rapid evolution of HIV-1 can also be attributed to viral escape of anti-HIV host immune
responses mounted through the course of infection. The early stages of HIV-1 infection
have been characterized into distinct Fiebig Stages I-VI27. At the start of infection,
humoral immune response against HIV-1 are delayed. Within 1 week, the first B cell
responses develop in the form of antibody-immune complexes, followed by anti-gp41
antibodies a few days later, and anti-gp120 antibodies several weeks later. Importantly,
these delayed antibodies provide no neutralization activity or selection pressure against
circulating viruses. Months after infection autologous strain-specific neutralizing
antibodies

emerge,

strains31,38,39,44.

but

provide

no

neutralizing

activity against

heterologous

Longitudinal analyses of the autologous antibody response against

contemporaneous and early viruses have shown that neutralizing antibodies drive viral
escape, as contemporaneous viruses are less sensitive to autologous antibody
responses than earlier viruses30,38,45–47. Structural and sequence analyses have shown
that this escape is mediated by mutations within the glycan shield of HIV-1 Env and
occurs through single amino acid substitutions, insertions and deletions48.

Despite significant challenges with rapid viral escape and low strain-specificity, depletion
of B cells using anti-CD20 antibodies in nonhuman primate models demonstrate that the
autologous antibody response maintains some clinical benefit during infection. Passively
transferred antibodies used as a prophylactic strategy against SIV or chimeric
simian/human immunodeficiency viruses (SHIV, described in the next section), in
nonhuman primates have shown that the dose and timing of autologous antibody
administration may have a role in limiting infection49–52. Additionally, recent advances in
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B cell cloning have led to the isolation of HIV-specific broadly neutralizing antibodies
(bNAbs), which are capable of potently neutralizing cell-free viruses from multiple clades
circulating worldwide53–56. Passive infusions of CD4 binding site (CD4bs) bNAbs have
recently entered the clinical trial pipeline and have shown significant and prolonged viral
load reduction in the majority of viremic participants

57

. Only 10-30% of infected

individuals produce bNAbs during the course of infection, with 1-2% having elite
neutralizing activity. While efforts to create an effective vaccine that will produce potent
bNAbs in vivo are underway, it is important to note that in passively infused bNAb trials,
successful viral suppression in some viremic individuals will not be achieved due to the
emergence of high-level resistant variants. Additionally, the finding of pre-existing bNAb
resistance in chronically infected individuals presents a significant challenge in using
passive infusion of bNAbs as a monotherapeutic cure strategy. Further discussion of
pre-existing resistance to the passively infused CD4 binding site antibody, VRC01, will
be described in Chapter 3 of this thesis.

For many infectious diseases, the presence of non-neutralizing antibodies have also
been implicated in disease prevention and control58. While neutralization activity of HIV-1
specific bNAbs requires high affinity Env binding of the variable Fab region of the
antibody, antiviral activity can also be mediated indirectly by activation of the Fc region
through interactions with the Fcγ receptor expressed on the surface of lymphocytes59.
Fcγ-mediated effector functions are facilitated through engagement of Fcγ with the Fc
region of IgG subtype antibodies and include antibody-dependent cellular cytotoxicity
(ADCC), antibody-dependent phagocytosis (ADCP) or antibody-dependent cellular viral
inhibition (ADCVI) on infected cells60. Previous studies have demonstrated several
protective roles mediated through Fc receptors engagement. In a multicenter AIDS
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Cohort Study, the ability of polyclonal antibodies to induce ADCC correlated inversely
with disease progression61. Additionally, antibodies with ADCVI activity develop weeks
to months prior to neutralizing antibodies, and have been shown to inhibit autologous
and heterologous strains of HIV-1 and are inversely correlated with plasma viremia

62

.

The protective effect mediated by ADCVI antibodies was also observed during oral
challenge with SIVmac251 in newborn macaques, where passive infusion of nonneutralizing, but potent ADCVI antibodies from the serum of SIV-infected macaques
protected newborns from infection63.

Differential Fc receptor binding capacities has been shown across various IgG
subclasses, where IgG1 and IgG3 are associated with increased affinity and stronger
activation of FcγR, while IgG2 and IgG4 have weak activity64. These less functional
antibodies compete for antigen occupancy with circulating IgG1 and IgG3. By depleting
IgG2 and IgG4 in vitro, a higher functional antibody response was observed, suggesting
an antagonistic role of IgG2 and IgG465. The protective effect mediated by IgG1 and
IgG3 were described in the RV144 phase 2B HIV vaccine trial (ALVAC-HIV vCP1521
prime and recombinant gp120 AIDSVAX B/E boost).

While poor humoral immune

responses were generated through vaccination, a reduced risk of HIV acquisition was
observed66,67. Further analyses of the subclasses of antibodies generated in vaccinated
recipients show that polyfunctional antibodies are able to simultaneously recruit multiple
effector functions, where IgG1 and IgG3 antibodies are associated with stronger
activation of Fc effector functions through increased affinity for the Fc receptor compared
to IgG2 and IgG4 antibodies65.
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The complexity and diversity of the autologous antibody response generated during viral
replication is partially driven by the constant evolution of HIV. This creates a “cat-andmouse” game of viral escape, where the neutralizing antibody responses is continuously
lagging behind viral evolution. Sequence analyses of viruses and isolated antibodies
from longitudinal time points of active viral replication adds to our understanding of the
molecular mechanisms that drive potent autologous antibody responses in vivo, and is
an important area of research for HIV-1 vaccine development.
Latency and persistence
The principal barrier to eradicating HIV-1 is the ability of the virus to integrate its genome
and establish a viral reservoir within a small pool of long-lived latently infected resting
memory CD4+ T cells. Characterization of reservoir dynamics is an important area of
study, as mechanisms of viral persistence under fully suppressive cART are not
completely understood.

Recent advances in next generation molecular sequencing

methods have revealed several findings that offer potential explanations. One
hypothesis is that there are ongoing, low levels of viral replication due to poor anatomical
penetrance of cART in lymphoid tissues68,69.

While suboptimal intracellular drug

penetrance is a valid concern, there is no clear evidence that supports reduced cART
concentration in lymphoid tissues in fully suppressed subjects when lymphoid tissue
samples are tested after six months of complete viral suppression with cART. Time
points earlier than six months cannot completely eliminate residual viremia. A second
alternative mechanism by which low level viral replication occurs during cART is
intracellular transmission through direct cell-to-cell contact70,71.

While infections

originating from a cell-free virus markedly decrease during cART, cell-to-cell
transmission of virus would be less sensitive to cART allowing the spread of virus to
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occur without acquiring drug-resistant mutations. These studies, however, have largely
been restricted to in vitro assays, with no direct evidence of cell-to-cell spread occurring
in vivo.

In contrast to ongoing viral replication during cART, others have described low-level
antigen-driven proliferation of CD4+ central memory cells and IL-7 mediated homeostatic
proliferation as an explanation for reservoir persistence72.

Independent sampling of

identical viral sequences 6+ months apart supports this hypothesis. Additionally, studies
using integration site analysis provide direct evidence of infected cell proliferation, further
demonstrating that sites of integration are variable and widely distributed throughout the
host genome. Identification of large expanded clonal populations within the reservoir
along with cells with the same integration site suggests that latently infected cells
clonally expand, thus contributing to the stability and persistence of the reservoir under
suppressive cART.

Furthermore, longitudinal sequence analysis of viruses sampled

before cART initiation and during structured treatment interruption in the Swiss HIV
Cohort Study show that HIV env C2-V3-C3 regions from rebounding viruses do not have
an increased genetic distance to the most recent common ancestor (MRCA) compared
to pretreatment viruses73. More recent studies, including one presented in Chapter 4 of
this thesis, support the hypothesis that the stability of the latent reservoir is instead
driven by the clonal expansion of latently-infected cells, as determined by single genome
sequence analyses of identical viruses from samples collected at independent time
points74–78.

In addition to reservoir persistence under cART, substantial efforts have been made to
determine the temporal dynamics of reservoir initiation in order to develop treatment
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strategies that limit or prevent reservoir establishment. These efforts were guided by
post exposure prophylaxis (PEP) studies in rhesus macaques, where cART was initiated
at days 3, 7, 10 or 14 post intrarectal exposure of SIV. After 24 weeks of fully
suppressive subcutaneous cART, viral rebound (plasma vRNA >50 copies/ml) occurred
in all animals, while animals treated with cART on day 3 experienced a 3-fold delay in
rebound kinetics compared to those treated at later time points79. Other studies in rhesus
macaques have shown that infection can be decreased significantly if PEP is
administered orally80 or subcutaneously81 within 72 hours of exposure of SIVmac251,
and followed by a brief period of daily dosing. These examples of increased protection
in animal models with early PEP initiation suggest reservoir establishment is not
immediate, though there is a finite window of opportunity where PEP can effectively
prevent permanent seeding of the viral reservoir. With this data, New York guidelines
now recommend that PEP is taken within 36 hours of possible HIV exposure and
continued for 4 weeks in order to reduce the chances of HIV acquisition82. Adherence
and completion rates of this short-term regimen, however, remain a significant challenge
as studies have shown that only 67% of individuals complete the 28-day course of PEP.
One method that has been used to improve retention rates include providing counseling
to individuals during PEP therapy. A meta-analysis of sexual assault victims who
received PEP show that psychological support through telephone, an adherence diary or
in-person counseling throughout the course of treatment is correlated with increased
drug adherence. This suggests that continuous emotional support may have a profound
impact on PEP efficacy and should be implemented when possible83,84.

Viral dynamics of SIVmac251 in vivo are substantially different from HIV-1 infection in
humans, with peak plasma viral load levels ranging from 2.1x107 to 7.4x107 vRNA
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copies/ml by two weeks post infection85, compared to a log fold decrease at 106 vRNA
copies/ml with HIV-1, peaking within 3 weeks post infection86. Additionally, variability in
the time to set-point viremia, differences in viral decay, as well as distinct innate and
adaptive immune responses in SIV infected macaques highlight key differences between
SIV and HIV-1 pathogenesis87. The creation of SHIVs, which contain an HIV-1 Env
cloned into an SIV backbone, helps to address the differences between SIV and HIV in
nonhuman primates88. Recently developed SHIVs incorporating HIV-1 Envs of clinically
relevant viruses demonstrate several key aspects of HIV-1 infection including productive
pathogenesis, high antigenicity, the ability to elicit autologous neutralizing antibodies,
viral persistence and progression to AIDS89. SHIV models will be an invaluable tool in
understanding the early events that guide the establishment of latency and resulting host
immune responses in the near future.
Combination antiretroviral therapy
Advances in the development of highly effective combination antiretroviral therapy
(cART) has led to improved patient outcomes, reduced HIV-associated comorbidity,
prolonged survival and decreased risk of HIV transmission90–92. The effectiveness of
cART is based off of a combinatorial dosage of drugs that affect several specific viral
enzymes responsible for replication, including RT, protease and integrase. Viral
suppression can be rapidly achieved to below levels of detection (<50 copies/ml) with
genetic screening for mutant viruses, and consistent treatment. The recommended
frontline cART regimen for most patients consists of two nucleoside reverse
transcriptase inhibitors (NRTIs) and an integrase strand transfer inhibitor (InSTI). Other
common clinical regimens include nonnucleoside reverse transcriptase inhibitors
(NNRTIs) or boosted protease inhibitors with two NRTIs. Drug tolerability, potency, and
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convenience of delivery are critical factors in achieving viral suppression. However, due
to a pool of long-lived latently infected cells, daily adherence of cART is required for the
lifetime of the patient93–96. Additionally, even as tremendous efforts have been made to
reduce barriers to access of long-term cART, the stability and size of the latent reservoir
remains unaffected by prolonged periods of suppressive cART, and as such, cART
alone will never be an effective method of eradicating HIV.

It is important to note that while early initiation of cART has substantial clinical benefits,
in countries with limited economic resources accessibility of cART remains a significant
barrier, thus highlighting the need of additional strategies to effectively target and
eradicate the viral reservoir. Proof-of-concept clinical studies exploring cART initiation
during the earliest stage of acute infection (Fiebig I) show that all patients experienced
viral rebound following cART cessation, further indicating rapid reservoir establishment
in humans

27

. Treatment during Fiebig I was found to have several clinical benefits

including preserved immunity, reduced HIV reservoir size, and no seroconversion.
However, additional studies assessing the magnitude of gastrointestinal (GI) tract
damage show that while individuals treated during acute infection resolved GI tract
inflammation and immune activation back to baseline with 24 weeks of cART,
histological evaluation of CD4+ T cells in the gut show that CD4+ T cells increase but do
not return to baseline after 96 weeks of cART. Attenuation of residual inflammation
within the GI tract during early cART is not to be overlooked, however, as activated cells
and increased inflammation are drivers of HIV persistence and returning these states
close to baseline levels can be an effective way to reduce the size of the reservoir97.
Control of viral replication with cART at the earliest clinically feasible time point is now
the standard of care, and “test and treat” strategies are implemented when possible in
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an effort to immediately reduce the size and genetic diversity of the reservoir as well as
the clinical manifestations of acute infection.
Clinical effects of analytical treatment interruption
While the advent of cART changed patient outcome during the HIV epidemic in the late
1990s by significantly reducing HIV-related morbidity and mortality, several limitations
and concerns regarding continuous cART treatment arose. In the early 2000s,
comorbidity, pill burden and adverse drug effects with cART were common reasons why
infected patients would switch drug regimens or pause therapy within the first year of
treatment despite the increased risk of viral rebound and progression to AIDS. This
regimen change or pause in therapy often led to reduced retention rates of long-term
suppression with cART, and increased the risk of drug resistance mutations98–100.
Although modern cART regimens have seen drastic improvements in drug adherence
due to greater tolerability and decreased pill burdens to once daily treatment regimens,
there is considerable interest in developing novel therapeutic strategies that would lead
to cART-free remission. Furthermore, access to daily cART remains a significant issue
for infected individuals living in regions of the world without adequate healthcare and
economic resources.

Studies that have tested the clinical benefits of cART interruption are known as
analytical treatment interruptions (ATI).

ATIs have been an invaluable method in

understanding the immune dynamics and viral kinetics that occur upon cessation of
cART.

From 2000-2006, ATI clinical trials assessed the clinical benefits and risks

associated with cART cessation in chronically infected individuals.

Participants

underwent weeks to months of ATI with periodic sampling of plasma viral load levels,
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CD4+ T cell counts, as well as other markers of immune activation. “Drug holidays”
were also prescribed, allowing participants to pause cART during weekends or holidays
in order to improve quality of life, decrease cART toxicity, and reduce the emergence of
drug-resistant variants101.

In 2006, concerns regarding metabolic and cardiovascular complications during
continuous, long-term cART in chronically infected participants were assessed in studies
utilizing episodic cART regimens in the Strategies for Management of Antiretroviral
Therapy (SMART) trial102. In the SMART trial, treatment interruption was guided by
CD4+ T cell counts and primary endpoints included increased development of
opportunistic disease or death from any cause with secondary endpoints being major
cardiovascular, renal, and hepatic disease. Ultimately, the SMART trial did not reduce
the risk of adverse events previously associated with continuous cART treatment, nor
did It boost host immune responses in the face of active viral replication.

Instead,

participants saw a significant increase in the risk of opportunistic infections and death, as
well as an increased risk to multidrug resistance. These concerns led to a brief halt in
prolonged cART interruption methods in future clinical trials.

Other studies have considered the time to cART initiation as a potential variable
affecting rebound kinetics and dynamics. Retrospective ATI studies on patients treated
with cART at the time of primary HIV-1 infection identified a 15.6% frequency of posttreatment controllers (PTCs) in acutely-treated patients, marked by sustained viral
suppression and significantly slower decline in CD4+ T cell counts after cART
discontinuation, vs. <0.5% in other patient cohorts89. While mechanisms of viral control
in acutely-treated PTCs is unclear, early cART initiation is thought to have significantly
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decreased the initial size of the viral reservoir, as well as preserve the capacity to
develop potent anti-HIV-1 specific host immune responses during ATI. Interestingly,
studies investigating rebound viral dynamics in individuals who began cART during
acute infection show no further delay in viral rebound than those who began cART
during chronic infection103.

Additional work assessing functional cure strategies with broadly neutralizing antibodies
in chronically infected patients have also relied on ATI methods as a means of assessing
the potency of bNabs on reducing the viral reservoir. While time to viral rebound was
significantly delayed compared to historical controls without bNAb intervention, the size
of the reservoir pre- and post-ATI and VRC01 infusion did not change. These studies
emphasize the importance of ATI methods in delineating latent reservoir dynamics and
viral diversity and establish that brief, closely monitored ATIs are safe and well tolerated
in chronically infected patient populations.

While significant efforts have been made to develop immunotherapeutics that target and
eradicate latently infected cells in chronically infected patients, the viral and host immune
dynamics that occur during ATI is still not completely understood. Therapeutic efficacy
of these novel treatment strategies is typically assessed by significant delays in the time
to viral rebound compared to previously conducted ATI trials in the absence of
therapeutic intervention (21 days post-ATI), but provides no information on the total size
or diversity of the reservoir. Others have used quantitative methods to determine the
size of the latent reservoir through HIV DNA and RNA analyses from PBMCs, but due to
the large portion of defective virions, these measures provide a vast overestimation of
the reservoir. Recently, single genome sequencing methods (SGS) of plasma viruses
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that arise at first detectable rebound provide a critical, but minimal snapshot of the
diversity of the latent reservoir (described in Chapter 2 of this thesis). For SGS, cDNA
derived from plasma vRNA is serially diluted to 1 copy per reaction, followed by direct
amplicon sequencing to preclude in vitro recombination and nucleotide misincorporation
errors mediated by Taq-polymerase. In contrast to bulk PCR methods, SGS allows for
the genetic inference of a single viral template rather than a composite of the sequences
comprising a major fraction of the viral quasispecies. Through SGS, one can identify
minority viral variants as well as linkage of mutations on the same genome85,99,104.
These robust sequencing methods can also be utilized in ex vivo quantitative viral
outgrowth assays (QVOA) in order to determine the composition of the viral reservoir
while the infected participant is cART-suppressed (described in Chapter 4 of this thesis).
While the QVOA assay provides valuable quantitative and qualitative information about
the replication reservoir in cART-suppressed participants, the assay itself is extremely
labor and material intensive, requiring millions of resting CD4+ T cells per assay.
Furthermore, when QVOA output is assessed by phylogenetic analyses with rebound
and pre-cART viruses, in the majority of infected participants, QVOA viruses form
distinct lineages and are not predictive of lineages that arise in vivo during treatment
interruption. These findings highlight that reservoir analyses by QVOA only provides a
minimal snapshot of the replication-competent viruses under cART.
Goals of this thesis
In this thesis, I address several key unanswered questions related to the viral and
immune dynamics that occur during ATI in two previously conducted clinical trials in
chronically infected participants suppressed with cART. First, I investigated the kinetics
and diversity of viral rebound using single genome sequencing methods and maximum

16

likelihood phylogenetic trees on plasma samples archived from first detectable rebound.
I hypothesized that sequence analyses would reveal multiple low-diversity lineages that
would evolve over the course of treatment interruption. With access to longitudinal ATI
samples, I found that rebound arises with 2 to more than 8 distinct clonal lineages, and
in the majority of participants, select lineages will either persist or clear over subsequent
ATI time points. Using autologous plasma from contemporaneous and subsequent
rebound time points, I found that the autologous antibody response generated during
rebound exerts antibody pressure on specific rebound variants and this pressure is
associated with the clearance of these lineages at later time points (Chapter 2). Second,
our lab led the virologic studies in the ACTG Clinical Trial, A5340. Here, I assessed
whether the broadly neutralizing antibody, VRC01, was able to exert additional immune
pressure on the latent reservoir during ATI. I hypothesized that VRC01 would delay the
time to first detectable rebound and select for VRC01 resistant variants (Chapter 3).
Through analyses of available pre-cART and rebound viruses from chronically infected
participants in this study, I found that there was an increased prevalence of VRC01
resistance, and this resistance led to only modest delays of viral rebound compared to
historic ATI controls. Additionally, through phylogenetic analyses, I determined that
VRC01 restricted the clonality of rebounding viruses, where highly resistant participants
had polyclonal rebound lineages, while participants with pre-circulating pre-cART viruses
with variable VRC01 resistance had monoclonal or oligoclonal rebound upon treatment
interruption and VRC01 infusion. Finally, with access to archived leukapheresis samples
from A5340, I asked whether ex vivo replication competent latent reservoir viruses could
predict the clonality of viruses that rebounded in vivo during ATI (Chapter 4).

I

hypothesized that sequence analyses would reveal that brief ATI would not lead to the
expansion of the viral reservoir. Quantitative and qualitative analyses of pre- and post-
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trial infected resting CD4+ T reveal that the size of the reservoir does not change upon
ATI, nor does it significantly alter the composition of replication-competent viruses in the
majority of chronically infected participants. Interestingly, through these analyses, I also
identified large, expanded clonal populations of viruses derived by QVOA and proviral
DNA sequencing. In participants where the majority of latent viruses represented a
single expanded clone, I did not find identical sequences from these clones in the
rebound viral quasispecies. Furthermore, I found that while these expanded clones did
not harbor increased VRC01 sensitivity, they have increased sensitivity to autologous
antibodies compared to rebound viruses, suggesting autologous antibodies are able to
exert some immune pressure from select latent viruses. Collectively, these data suggest
that multiple latently infected cells are able to reactivate in vivo to establish viral rebound
in chronically infected participants. The diversity of the rebounding viral quasispecies,
however, is influenced by autologous antibodies and additional immune pressures
exerted by infused broadly neutralizing antibodies. Pre-existing resistance to the
antibody response may affect the ability of these variants to persist over subsequent
viral rebound time points. Additionally, through the assessment of pre- and post-trial
latent, pre-cART and rebound viruses from the A5340 clinical trial, I conclude that brief,
closely monitored ATIs are safe and well tolerated, and do not lead to severe clinical
risks or expansion of the viral reservoir as observed in previously conducted historic ATI
trials.
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Autologous antibody responses drive viral diversity during rebound after
analytical treatment interruption
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Abstract
Analytical treatment interruptions (ATI) in chronically infected, cART-suppressed
participants provide a unique opportunity to assess the characteristics of viruses that
emerge from the latent reservoir. This assessment of rebound viruses can be used to
inform future therapeutic strategies aimed at reducing or clearing the reservoir to
achieve cART-free HIV remission. Previous clinical trials utilizing ATI methods have
determined that in the majority of participants, plasma viremia can be observed within 24 weeks of cART cessation, though the viral and immune dynamics that occur during
this period are unclear. In this study, I used single genome sequencing methods (SGS)
and neutralization assays on archived rebound plasma samples from a previously
conducted ATI clinical trial to describe the genotypic and phenotypic characteristics of
viruses that emerge from the latent reservoir. Consistent with recently published studies,
I observe that first detectable viremia occurs within a median of 4 weeks post-ATI, and
arises from multiple latently infected cells. Additional sequence analyses of longitudinal
rebound time points also revealed that select rebound variants can either persist or clear
from the viral quasispecies, and newly emerging, distinct viral variants can emerge over
time. Of note, early rebounding viruses that were cleared at subsequent ATI time points
were shown to have greater sensitivity to contemporaneous and longitudinal plasma.
These data demonstrate that the autologous antibody response is able to exert selective
immune pressure on viruses emerging from the reservoir, thus influencing the
composition of the rebounding viral quasispecies.
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Introduction
The primary barrier to HIV cure is the persistent latent reservoir. Combination
antiretroviral therapy (cART) potently suppresses ongoing virus replication, but it does
not eradicate latently infected cells. When cART is stopped, reactivating virus quickly
reinitiates systemic replication in the vast majority of people living with HIV. Thus, the
study of viral rebound allows a better understanding of the underlying latent reservoir
and the impact of eradicative strategies.

Studies involving viral rebound after an analytical treatment interruption (ATI) have been
conducted for multiple reasons over the past 30 years. Early trials tested the
immunologic and drug-sparing effects of relatively open-ended ATI, with CD4+ T cell
counts and viral load thresholds used as cART restart criteria1–3. These trials showed
minimal immune enhancement as a result of rebound viremia in terms of clinical or
immunologic outcomes. Further, extended periods of rebound viremia were associated
with poorer clinical outcomes, including a significant increase in the risk of opportunistic
infections and death, as well as an increased risk of developing multidrug resistance to
cART1. Collectively, these ATI studies show minimal immune enhancement from
rebound viremia in terms of clinical or immunologic outcomes, resulting in reluctance to
conduct clinical trials involving prolonged ATI. Recent studies of short, closely monitored
treatment interruptions, in contrast, have provided reassurance that ATIs can be
conducted safely, with little or no measured change to immune parameters or the size or
composition of the latent reservoir after re-initiation of cART4–7. Moving forward, the
ability to suppress or delay viral rebound remains a key goal of clinical trials of HIV
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therapy and cure strategies. Thus, as novel treatment strategies targeting the latent
reservoir have emerged, closely monitored analytical treatment interruptions (ATI) of
cART are likely to remain critical components of HIV clinical trials.

Having access to clinical trial samples at the time of viral rebound also allows the unique
opportunity to examine viruses that until very recently were part of the replication
competent latent reservoir. Recent studies of viral rebound, including a human clinical
trial of intensively monitored ATI by Rothenberger and colleagues, demonstrated that
virus reactivates from multiple infected cells at sites throughout the body14. Studies
sampling plasma virus weekly or bi-weekly support these findings, suggesting that initial
plasma rebound virus is comprised of a diverse virus population that reactivated from
multiple, genetically distinct, latently infected cells. Two reports regarding two
independent ATI trials found that viruses arising during rebound were not identical to
genetically intact or replication-competent viruses from the periphery15,16.

The viral

kinetics of rebound in the days and weeks after initial viremia, however, are less well
characterized. Further, the role of host immune responses in driving virus evolution in
the days and weeks after durable cART suppression are unclear. As the field moves to
test immunologically active interventions and other cure strategies within the context of
ATI, the viral and immune parameters of rebound will become even more relevant.

Here, I performed in-depth analyses on the virus populations that rebound in participants
undergoing a prolonged ATI in a previously conducted clinical trial8.

Using single

genome sequencing (SGS), phylogenetic analyses, and neutralization assays of Env
pseudotypes against contemporaneous and longitudinal plasma, I found that the virus
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populations circulating systemically during ATI substantially evolve over time and that
autologous antibody responses are an important driver of that process.

Results
Participant characteristics
To evaluate the viral and immune kinetics of rebound, we studied samples from a
previously conducted clinical trial that tested the effect of ATI in participants who initiated
cART during chronic infection and had been durably virally suppressed on cART for at
least six months (NCT00051818)8. The trial compared the effects of a single openended ATI for up to 47 weeks, and multiple-ATI with structured ATIs of 2, 4, 6, and 12
weeks in duration. The time to rebound, adverse events, viral setpoint pre and postinitiation of cART, immune parameters and effectiveness of resuppression on cART
were examined. Results demonstrated no significant differences in clinical outcome
between the two arms. For our analyses, we randomly selected participants (n=11 from
the single ATI arm and n=2 from the multiple ATI arm) who experienced viral rebound to
>1,000 copies/ml and for whom plasma samples were available. Demographic and
clinical characteristics of the 13 participants of this study are described in Table 2.1. In
summary, these 13 participants’ characteristics were similar to the parental trial cohort,
with a median age of 42 years (single-ATI) and 46 years (multiple-ATI); these
participants were 80% male, 40% African-American, 40% Caucasian, 20% LatinX, and
reported sexual HIV transmission. They had been on ART for a median of 4.5 years,
with a median CD4 T cell count of 637 cells/mm3 (single-ATI) and 658 cells/mm3
(multiple-ATI) at enrollment. The participants were on ART regimens of either protease
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inhibitors (n=6) or non-nucleosidase reverse transcription inhibitors (n=8) and two
NRTIs. In the trial, participants stopped their ART and had plasma samples collected
every two to five weeks.

Kinetics and clonality of viral rebound
Viral kinetics of rebound for the single ATI participants are shown in Figure 1.
Participants were sampled every four to five weeks, and 10 of 11 had experienced viral
rebound by week 4, consistent with other reports of time to rebound after ATI in the
absence of any intervention2,5,7,14,17–19. Plasma viral loads at week 4 post-ATI ranged
from 834 to 26,468 copies/ml.

To estimate the number of virus-infected cells rebounding from latency to contribute to
systemic rebound, we performed SGS of env on the plasma virus from first detectable
viremia in eleven participants. Depending on plasma viral load, we performed either full
gp160 env sequencing (n=9) or gp41 env (n=2).

ML phylogenetic trees of env

sequences are shown in Figure 2. Maximum within-participant genetic diversity at this
time point ranged from 1.1% to 6.1%, reflecting the diverse virus populations comprising
the latent reservoir in individuals initiating ART in chronic HIV infection. Within these
diverse virus populations, discrete identical and low-diversity lineages can be discerned
in multiple participants, reflecting clonal expansion from a recently reactivated virusinfected cell. To better understand early evolution during viral rebound, the mathematical
model and Monte Carlo stimulation presented by Lee et al. can be used to distinguish
between two unique variants8,9.

We estimate that the time to cART washout is

approximately two weeks, and that immune selection events have not yet occurred
during this period. Here, I used the conservative cut-off of 0.15% diversity (or ~3
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nucleotides per gp160 env sequence) to discriminate between virus evolution during
viral rebound vs. prior to ART initiation, and estimate the minimal number of virus
populations contributing to systemic viral rebound. Further, when the total rebound viral
quasispecies is analyzed together, the data fails to conform to a Poisson distribution, but
when each lineage is examined independently, the Poisson distribution is maintained.
Examining each of the participants, we find multiple genetically distinct virus populations
establish rebound viremia with between 2 and more than 10 founder virus populations
fitting independent Poisson distributions, with a median of distinct 5 populations in each
participant. For example, Participant S25’s (Fig 2A) viruses cluster in four genetically
distinct lineages, suggesting rebound from at least four distinct virus-infected cells.
Participant S21’s viruses (Fig 2B) cluster into three distinct populations (two lineages
with multiple closely related viruses, with diversity <0.15%), and a single genetically
distinct sequence representing a less deeply sampled lineage. While these estimates
have several important caveats, including the limited sampling depth and issues of
recombination and APOBEC-mediated mutation, these results mirror those of other
studies estimating the clonality of the rebounding virus population14–16.

When I

examined the relationship between time to rebound, viral clonality, and viral load at first
detectable rebound in this single ATI cohort, I found no significant correlation between
these variables (Spearman’s rank correlation coefficient p>0.05, Figure 2.3), suggesting
that the number of founder viruses does not affect the timing or magnitude of viral
rebound.

Rebound virus populations rapidly evolve over time and early dominant viruses
are cleared
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To assess changes in rebound diversity over time, we performed SGS of HIV-1 Env over
the duration of up to 47 weeks of ATI in eight participants with available longitudinal
sampling and analyzed each participant’s sequences in ML phylogenetic trees (Figs
2.4). In all participants, total virus diversity increased (In participant S25, max diversity
at first detectable rebound was 1.1% within 4 weeks of ATI vs. 11.9% within 47 weeks of
ATI). Across the cohort, the increased diversification over time was driven by expansion
of the initial virus populations sampled at first detectable rebound and the addition of
new, genetically distinct lineages arising from continued reactivation from latency or the
recombination of previously sampled lineages. Many of the virus lineages sample at first
detectable rebound persisted over time, with identical or similar env sequences sampled
at later time points. In the majority of participants, however, a substantial number of the
rebound founder lineages (those sampled at first detectable rebound) were not sampled
longitudinally, suggesting they were cleared from circulation or substantially reduced in
relative frequency compared to other variants. For example, in Participant S53, the 4
lineages sampled at first detectable rebound (week 4 post-ATI, in black in Fig. 2.4B) are
not sampled subsequently at weeks 8, 12 or 17 post-ATI. In a similar but more extreme
example, participant S25 (Fig. 2.4D) had 5 genetically distinct lineages with a max
diversity of 1.1% sampled at first detectable rebound. Four weeks later, all of these
viruses were cleared, and a genetically distant virus population with a max diversity of
11.6% was sampled, which persisted for the next 30 weeks. To be sure sample mix-ups
were not responsible for this extreme shift in virus populations, we performed
mitochondrial sequencing of host DNA in each plasma sample, which confirmed the
shared identity of these samples. In other participants, including S05 (Fig. 2.4A) and S60
(Fig. 2.4C), there was a mixed picture, with some initially sampled lineages persisting
and others being cleared. In participant S05, plasma virus at 4 weeks post-ATI clustered
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into 4 lineages; the most populous of these lineages (39% total sequences) is not
sampled 6 weeks later, while the 3 relatively minor lineages persist, with identical or
nearly identical viruses sampled at week 10. Of the seven participants with adequate
longitudinal sampling, two participants had all initial lineages cleared by the next time
point, four had most or the predominant lineage cleared by the next timepoint, while just
one participant had the majority of lineages persist.

With the caveats that limited

sampling depth and recombination may account for some virus population shifts, these
dramatic shifts in virus populations over the first weeks of rebound suggest a strong
selective pressure against cleared viral lineages.

Autologous neutralizing antibody responses (nAb) drive virus population shifts
during early rebound
While autologous nAbs have been shown to drive virus clearance in acute and early
infection20–25, titers wane substantially during ART suppression26. Thus, it is unclear
whether they can drive viral clearance during early ATI and rebound.

To test the

hypothesis that autologous nAb responses have a role in shaping the rebound virus
quasispecies, we generated Env pseudoviruses from the consensus of early rebound
lineages that persisted or were cleared in participants S05, S60 and S53 and assessed
their neutralization sensitivity to early ATI plasmas (see Fig 2.4 for cloned Envs).

Figure 2.5A and B display the autologous plasma nAb titers against virus lineages that
were either cleared or persisted in these three participants. In participant S05, initial nAb
titers at the time of first detectable rebound (week 4 post-ATI) are modest against the
circulating rebound virus populations (titers between 1:200 and 1:400). By week 10,
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when the cleared viruses are no longer sampled, the titers against the cleared viruses
have markedly increased, while the titers against the lineage that persist remain modest.
In participant S60, first sampled at week 5 post-ATI, titers against the viruses that will
ultimately be cleared are already about 1 log higher than against those that persist; the
increased titers against the cleared viruses remain higher through week 13. By week 17
post-ATI, 9 weeks since the cleared viruses were last sampled, the nAb response to the
persisting lineages appear roughly similar. In participant S53, nAb titers increase more
than 1 log between weeks 4 and 8, coincident with the clearance of the rebound
founding virus populations. When the titers are compared at the time point in which the
population shift occurred across the 3 participants, the autologous nAb responses were
statistically greater against cleared than persistent viruses (Fig. 2.5C, median reciprocal
IC50 titer 906 vs. 153, p=0.0286 by Wilcoxon/Mann-Whitney test).

To estimate the timing of the emergence of autologous nAb response during ATI, we
tested the potency of plasma IgG prior to and during ATI in two participants. At least 1ml
of pre-ATI plasma (timepoint 0) was heat inactivated and IgG was further purified from
circulating cART through column isolation with the rProtein A/Protein G GraviTrap (GE
Healthcare), followed by quantification with the Pierce BCA Protein Assay kit. IgG was
then diluted to meet circulating IgG concentrations found in human plasma during cART
suppression10 (see methods). In each participant, IgG increased in potency with the
emergence of antigen in viral rebound (Fig. 2.5D). The quantity of IgG required to reach
an IC50 against early rebounding variants was between 9-fold and 33-fold greater than
total µg IgG required from contemporaneous plasma (P=0.0079, Wilcoxon/MannWhitney test), suggesting anti-HIV IgG responses are modestly present prior to viral
rebound and rapidly amplify within the first weeks of viral rebound. Additionally, strain
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specificity can also be observed in pre-ATI plasma, where persisting viral lineages had
an IC50 of >2000µg/ml IgG, while cleared lineages were neutralized with 174 µg/ml to
1295 µg/ml of IgG.

Autologous nAb responses drive virus selection through sequential ATIs.
We next asked whether nAb responses would similarly drive rebound virus evolution in
the participants undergoing multiple structured ATIs. I studied two participants who
underwent three serial ATIs of 2, 4, 6 and 12 week intervals followed by brief periods of
virus suppression with cART (Fig. 2.6A and C). In both participants, each ATI led to
rapid viral rebound within 2-5 weeks. We generated gp160 env sequences via SGS for
each participant using samples from the time of first detectable plasma viremia over 200
copies/milliliter. For participant S04, viruses from first detectable viremia in ATI timepoint
1 (ATI 1) clustered into six lineages (three major lineages and three genetically distinct
single viruses, Fig. 2.6B). For participant S23, virus during ATI 1 did not rise over 200
copies; initial plasma rebound during ATI 2 was characterized by 7 lineages (Fig. 2.6D).

To determine the effects of nAbs on virus evolution, we examined the viruses that
emerged during subsequent ATIs. A significant limitation to this analysis is the minimal
time of ART suppression between each ATI time point. Because there was not enough
time for the virus population to re-enter steady state latency11, rebound virus during
subsequent ATIs likely arose either from recently infected, short-lived cells or ongoing,
low-level virus replication in the absence of long-term, durable ART suppression. We
reasoned, therefore, that virus circulating during subsequent ATIs would be biased
towards the virus populations reactivating during the initial ATI.
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What we found,

however, was that in both participants several of the initial virus populations were
cleared. In S04, one of the three major and all three minor lineages failed to be sampled
subsequently (Fig. 2.6B).

Two of the original virus populations persisted and were

sampled along with new distinct virus populations at subsequent ATI timepoints. In
participant S23, three of seven initial lineages in ATI 2 were no longer sampled, while
four others persisted through ATIs 3 and 4 (Fig. 2.6D). When representative viruses
from persisting and cleared lineages from each participant were cloned and tested as
pseudoviruses for sensitivity to autologous plasma (Fig. 2.6E), the cleared viruses had a
trend towards higher autologous nAb titers than the persisting at ATI 2, meaning that the
cleared viruses were more neutralization sensitive to paired contemporaneous
autologous plasma than persisting viruses (IC50 reciprocal plasma dilution for persisting
lineages=208 versus cleared lineages=0.223, P= 0.200 by Wilcoxon/Mann-Whitney
test). Thus, our results from multiple-ATI participants are consistent with our findings
from the single-ATI participants.
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Tables

Table 2.1 Single-ATI and multiple-ATI participant demographics
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Figures

Figure 2.1 Kinetics of viral rebound from single-ATI participants
This graph displays measured plasma HIV-1 RNA viral loads from the nine participants
who underwent single-ATI. Shapes represent time points in which archived plasma was
available for single genome sequencing and neutralization assays. Tick marks represent
time points where plasma was not available for analysis.
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Figure 2.2 Maximum-likelihood phylogenetic trees of SGS-derived gp160 env or
gp41 sequences from single-ATI participants (A-K: S05, S21, S28, S29, S33, S53,
S61, S62, S60, S25 and S32). Env sequences from first detectable rebound are shown
in black squares. Genetic distance is shown by the scale bar, indicating percent
difference.
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Figure 2.3 Correlations between viral load, the number of rebound/founder
lineages, and weeks post-ATI at first detectable rebound. No correlation was
observed in either measure, (A)P=0.226, (B)P=0.81, (C)P=0.217, as determined by
Spearman’s correlation coefficient.

42

Figure 2.4 ML phylogenetic trees of SGS-derived HIV-1 gp160 or gp41 from
longitudinal ATI time points Participants S05, S53, S60 and S25 shown above (A-D).
Squares depict a single virus. Black, green, blue, and red depict viruses sequenced
from first, second, third and fourth ATI time points, respectively. Blue circles (persisting
lineages) and red triangles (cleared lineages) highlight first detectable rebound gp160
envs that were used for Env Pseudotype generation and neutralization analyses.
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Figure 2.5 Strain-specific autologous antibodies develop during ATI. A. Participants
S05, S60 and S53 have persisting (circle) and cleared (triangle) viruses with differing
neutralization sensitivity to antibodies from contemporaneous and longitudinal ATI time
points. B. Summary of IC50s. C. Isolated IgG from pre-ATI time points from participants
S53 and S60 show neutralizing antibody responses develop during rebound. D. Total
IgG required to reach IC50s against persisting and cleared viral lineages.
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Figure 2.6 Viral kinetics, dynamics, and autologous antibody responses in
multiple-ATI participants. Participant S04 shown in (A) and (B), participant S23 shown
in (C), (D). (E) The autologous antibody response at first detectable rebound in ATI time
points 1-4 displayed as reciprocal IC50 plasma dilution. The HIV-1 Env variant cloned for
neutralization assays can be found in each participant’s respective phylogenetic tree,
indicated as a triangle (cleared lineage) or circle (persisting lineage).
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Discussion
While cART is effective at stopping ongoing virus replication, sustained viral suppression
currently requires a lifetime of daily cART due to the persistence of latently infected cells.
These cells are the target of novel therapeutics that aim to eradicate or suppress the
latent reservoir to induce cART-free remission. Without a validated biomarker of the
reservoir, however, ATIs are an important empiric test of the efficacy of suppressive or
curative strategies against HIV. Many of these strategies engage the human immune
system, making elucidation of the viral dynamics and host immune responses during ATI
and rebound highly relevant.

Several parallels exist between the biology of HIV transmission and acute infection and
that of viral rebound during ATI. In both scenarios, a viral inoculum initiates systemic
infection and is met with innate and adaptive immune responses. In acute infection, the
size of the inoculum12–15, and the timing of the ensuant innate16–19 and adaptive
responses20–24 have been well characterized. Rebound after ATI has recently been
shown in several human studies to follow reactivation of multiple viruses from multiple
sites25. The timing and magnitude of innate and adaptive immune responses, however,
are not well characterized. The kinetics of adaptive immune responses, in particular, are
highly relevant to the array of CTL and Ab-based therapeutics being currently
developed.

Previous studies have shown that exhausted CD8+ T cells expand and CD4+ T cells
decline with increased viral replication during primary infection26 and viral rebound2,
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suggesting a similar temporal association between antigen load and anti-HIV T cell
responses. Additionally, upon initiation of cART in both groups, rapid reconstitution of
lymphocytes, cytokines, chemokines and additional elevated inflammatory markers is
observed, though these levels do not completely return to baseline levels
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. Partial

immune reconstitution can also be observed in participants who underwent multiple ATI
strategies2. Key differences between transmission and rebound include the number of
variants that establish plasma viremia.

During acute infection, 80% of mucosally

transmitted variants are from a single transmitted founder virus (T/F) in HIV-1 clade B
and clade C infections13,30, while multiple genetically distinct variants establish viral
rebound25. Additionally, while increased titers of neutralizing antibodies against
heterologous isolates were found at 8 weeks of ATI and were associated with lower viral
loads during rebound, no analyses of strain-specific neutralization were measured31.
Determining the kinetics and potency of the host antibody response against autologous
viruses is pivotal to our understanding of viral rebound dynamics during ATI and could
potentially provide an additional mechanism by which neutralization-sensitive latent
viruses are unable to sustain systemic replication in the absence of cART.

Here, we used archived plasma samples from a previously conducted single-ATI and
multiple-ATI clinical trial to assess the genotypic and phenotypic characteristics of the
rebounding viral quasispecies. Consistent with previous ATI trials1,7,26,32,33, we found that
viral rebound occurs within 2-4 weeks of ATI (median 4 weeks) (Fig 1) while
phylogenetic analyses of plasma viruses from this time point revealed a substantial
increase in diversity (range, 1.1-6.07%) compared to the diversity of viral populations
observed during acute infection (range, 0.08-0.47%)13, suggesting viral and host immune
dynamics during rebound are distinct from early infection.
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A hallmark of chronic HIV-1 infection is the expansive intra-patient genetic diversity
driven by the accumulation of viral immune escape mutations as well as rapid and errorprone replication rates. While cART can reduce plasma viral loads to undetectable
levels, infected cells with genetically distinct viruses can remain transcriptionally inactive
until cART is removed, thus contributing to the overall diversity of the latent reservoir. In
this study, we identified multiple genetically distinct viruses emerging from latency
utilizing SGS methods on plasma viruses from first detectable rebound by identifying
clonal viral lineages.

The criteria we used to identify a clonal virus includes the base

pair in vivo evolution rate of HIV-1 (4.1-1.7x10^-3 per base per cell), multiplied by the
length of gp160 (approximately 2,700 nucleotides) and gp41 (1,400 nucleotides). Using
these criteria, we find that the maximum number of mutations allowed from the
consensus viral sequence is 3.78 mutations, and 1.96 mutations respectively,
accounting for minor PCR-induced in vitro errors. We identified 2 to more than 8 clonal
lineages per participant at first detectable rebound, with evidence of recombinant viruses
scattered throughout the phylogeny (6 of 11 participants).

The accumulation of

recombinant rebound viruses during ATI was recently described in an ATI trial with
infusion of 3BNC117, a CD4 binding site broadly neutralizing antibody6. In this study,
parent viruses were frequently found in the latent reservoir, but did not productively
expand in vivo, suggesting that the increase in rebound virus diversity can be attributed
to recombination events occurring with two or more distinct reservoir viruses upon cART
cessation. While our analyses were limited to circulating plasma viruses, we identified
multiple recombinant variants at first detectable rebound in addition to parent viral
strains. These findings suggest that while recombination events may contribute to viral
diversity, they are not the only factor guiding systemic virus replication during rebound.
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We next assessed correlations between rebound viral diversity, viral loads, and time to
first detectable rebound. According to our results, no significant correlation was
observed between viral load and the number of clonal lineages at first detectable
rebound (P=0.226), viral load and the number of weeks to first detectable rebound
(P=0.81), or the number of weeks of detectable rebound and the number of clonal
lineages (P=0.217) (measured by Spearman’s correlation coefficient).

The genetic complexity of the viral reservoir in chronically infected individuals can be
observed by sequence analyses of the viral quasispecies over longitudinal ATI time
points. In eight participants with sufficient plasma samples for SGS analyses, we
observe the emergence of multiple, genetically-distinct viruses throughout the course of
ATI, as well as the persistence and clearance of select viral lineages. The viral rebound
dynamics observed at baseline highlight how quickly the diversity of the viral
quasispecies can accumulate in the absence of cART and significant selection
pressures. This is in contrast to Bar et al.’s findings with ATI and VRC01 infusion, where
VRC01 is able to exert potent selection pressure on pre-existing VRC01 sensitive
variants, resulting in monoclonal/oligoclonal populations of VRC01-resistent rebound
lineages33. These data led us to investigate possible host-mediated mechanisms guiding
the clearance of select viral lineages.

Neutralization sieve analysis from autologous antibodies can elucidate mechanistic
correlates of immune protection by blocking the transmission of more sensitive viruses34–
39

. While neutralization sieve analyses have been extensively studied in vaccine trials to

identify viruses that establish “breakthrough” infections40–43, the kinetics and potency of
neutralizing antibodies that arise during ATI have not yet been characterized. Using
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archived plasma samples and Env pseudotypes of consensus envs from cleared and
persisting lineages, we asked whether autologous antibody responses generated at the
time of virus reactivation implemented significant neutralization pressure on select
lineages, thus preventing ongoing persistence at later ATI time points. In four out of nine
participants, we found that cleared lineages had a 3.4-fold increase in sensitivity to
autologous plasma (mean reciprocal plasma dilution=631.7, P=0.0079) (Fig. 2.5B).
Isolated IgG from pre-ATI time points show up to a 33-fold increase in total µg IgG
required to neutralize 50% of early rebounding variants, suggesting anti-HIV antibodies
rapidly emerge shortly after viral rebound (Fig. 2.5D).

The viral and immune dynamics under multiple courses of ATI are unclear. In this study
we assessed viral rebound and autologous antibody responses in two participants who
participated in multiple ATIs conducted in 2, 4, 6 and 12 week intervals to determine
whether autologous neutralizing antibodies prevent the persistence of rebound lineages
over episodic ATI time points. While the brief periods of cART treatment of ATIs prevent
an accurate analysis of viruses emerging from latency, similar to our findings in singlearm ATI, multiple latently infected cells contribute to viral rebound at each ATI time point.
Interestingly, we also observe viral persistence during multiple ATI timepoints,
demonstrated by multiple identical viruses arising at first detectable rebound, as well as
clearance of specific viral lineages. Cleared viral lineages were also found to be more
sensitive to autologous antibodies collected from the first detectable rebound time point
of each ATI period in participant S04 (1 of 2 cleared) and S23 (2 of 3 cleared), consistent
with our previous findings with cleared viruses from single-arm ATI participants. These
data suggest that the initial autologous antibody response generated during the first ATI
time point is able to apply a neutralization sieve against select rebounding variants at
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multiple-ATI timepoints, even as viral loads decrease to undetectable levels under
intermittent periods of cART.

This study has several important limitations. First, our analyses were limited to
participants with available plasma to assess by neutralization assays and/or SGS
methods. Further work on larger and more diverse cohorts with extensive samples of
archived plasma meeting sequencing viral load requirements is warranted. Secondly,
viral load analyses in the single-arm ATI cohort began after 4 to 5 weeks of treatment
interruption. This delay in viral load sampling fails to capture early, minor rebounding
variants that may have emerged sooner, but were rapidly cleared from the viral
quasispecies or were less fit compared to the dominant lineage, thus preventing
accurate assessment of first detectable rebound viruses.

Our likelihood of missing

infrequent variants was also increased by our limited sampling depth by SGS methods.
Power studies on plasma vRNA sequences show that when the total number of
sequences (n) is ≥30, one can be 95% confident not to have missed any variant that
comprised at least 10% of the total viral population, whereas when n is between 10 and
20, there is at least an 80% chance to detect a variant represented in ≥15% of the
population13. In the present study, 11/11 single-ATI participants and 1/2 multiple-

ATI participants had less than 30 sequences available for analyses for at least
one ATI timepoint. Prolonged ATI studies with greater plasma sample availability may
help to address this sampling issue. Third, in the multiple-ATI cohort, it is notable that
while both participants experienced waning viral loads upon cART reinitiation between
ATI time points, they did not achieve complete (<50 copies/ml) and prolonged viral
suppression throughout the course of this study.
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The short period of cART and

incomplete viral suppression between treatment interruptions prevent a clear distinction
between viruses rebounding from latency and ongoing replication and infection of shortor medium-lived cells. Future studies assessing participants with multiple ATIs should
consider at least 6 months of cART and undetectable plasma viremia before reinitiating
ATI to provide a more accurate assessment of viruses rebounding from latency.
In summary, this study highlights several distinctions between HIV-1 transmission and
viral rebound. Consistent with recently published studies, I found that unlike HIV-1
transmission, viral rebound is quickly established by multiple, distinct viral lineages
reactivating from latency4,7,25,32,33. Additionally, longitudinal sampling of rebound variants
demonstrates that early rebound lineages are susceptible to nAb immune pressure,
resulting in selective sweeps of nAb-sensitive lineages within weeks of ATI. This finding
is notable as previous studies have suggested that memory B cell responses have a
decreased functional profile once chronic HIV infection has been established44,45.
Instead, my data shows that strain-specific nAbs are preserved during cART
suppression, and are able to produce strain-specific nAbs within 4 weeks of ATI,
resulting in viral clearance of nAb-sensitive lineages at subsequent ATI timepoints of up
to 78 weeks. This autologous antibody sieving effect occurs more rapidly than in chronic
infection, where strain-specific neutralizing antibodies take years to develop37.
Additionally, through IgG isolation of pre-ATI plasma, I show that strain-specific
antibodies can be found in the plasma at pre-ATI timepoints, suggesting plasma B cells
are actively producing low titers of nAbs in the absence of plasma viremia. This finding
is significant, as it provides an additional host-mediated mechanism of viral control
during ATI. Together, these virologic and immunologic findings provide new insight on
the baseline events that occur during ATI and viral rebound, which will be critical for our
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understanding of treatment efficacy in future curative therapies operating under ATI
conditions.
Materials and Methods
Clinical trial and participant selection
We studied eleven participants from a previously conducted trial comparing a single vs.
multiple ATI schema (NCT000518182). We randomly selected eleven participants with
available plasma samples and viral rebound ≥ 1000 copies/ml from the single ATI arm
and two participants from the multiple ATI arm.
Institutional Review Boards.

The study was approved by local

Eligibility criteria for the clinical trial are published, but

generally included >18 years of age, cART suppression <500 copies/ml for more than 6
months, <50 copies/ml at recruitment of ATI study, CD4+ counts >400 cells/µl on ART
and a nadir no less than 100 cells/µl. For gp160 and gp41 env analyses during viral
rebound, all participants were selected based on first detectable rebound plasma viral
loads >1000 copies/ml

and >800 copies/ml, respectively, and successful viral

suppression <50 copies/ml after cART reinitiation. The trial participants from the singlearm ATI cohort received continuous cART for 1 year, followed by open-ended ATI with
the first plasma collection at 4 to 5 weeks, and biweekly monitoring of plasma viremia.
Multiple-arm ATI participants interrupted therapy sequentially for 2, 4, 6 and 12 week
intervals sequentially, with 2, 12 and 16 weeks of cART-mediated resuppression
between each ATI and biweekly monitoring and a final open-ended interruption for up to
1 year. In both cohorts, participants on NNRTIs were instructed to stop these drugs one
day earlier than the remaining drug regimen. The primary outcome of the parent study
was time to viral rebound during ATI (>5000 copies/ml).
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Viral RNA extraction, cDNA synthesis, single genome sequencing (SGS)
SGS enables proportional representation of the complex HIV-1 virus quasispecies with
linkage across the sequenced region with minimal in vitro errors46. Viral RNA extraction,
cDNA synthesis, and SGS were performed to amplify gp41 or gp160 env as previously
described33. In order to ensure a majority of sequences would be generated from a
single template, cDNA was diluted so that PCR positive wells were < 30% of the total
products. Single cDNA templates for gp41 were amplified with the following hemi-nested
gp41 primers: 1st and 2nd round forward primer for gp41, FOR13: GAGAAAGAGCAGAAGACAGTGG ; 1st round reverse primer 3Envout: TTGCTACTTGTGATTGCTCCATGT;
2nd round reverse primer 3Envin: GTCTCGAGATACTGCTCCCACCC. PCR was
performed in MicroAmp 96-well reaction plates (Applied Biosystems, Foster City, CA)
with the following PCR parameters: 1 cycle of 94°C for 2 min; 35 cycles of a denaturing
step of 94°C for 15 s, an annealing step of 55°C for 30 s, an extension step of 68°C for
1min 30 s, followed by a final extension of 68°C for 10 min. The product of the 1st round
PCR was subsequently used as a template in the 2nd round PCR under same conditions
but with a total of 45 cycles. 1.5kb amplicons were inspected on precasted 1% agarose
E-gels 96 (Invitrogen Life Technologies, Carlsbad, CA). All PCR procedures were
carried out under PCR clean room conditions using procedural safeguards against
sample contamination, including pre-aliquoting of all reagents, use of dedicated
equipment, and physical separation of sample processing from pre- and post-PCR
amplification steps. Single cDNA templates for gp160 were amplified with the following
nested env primers: 1st round forward primer 5out: TAGAGCCCTGGAAGCATCCAGGAAG,

2nd

round

forward

primer

5in:

CACCAAGCTTTAGGCATCTC-

CTATGGCAGGAAGAAG ; 1st round reverse primer 3Envout: TTGCTACTTGTGATTGC-
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TCCATGT; 2nd round reverse primer 3Envin: GTCTCGAGATACTGCTCCCACCC. PCR
parameters included: 1 cycle of 94°C for 2 min; 35 cycles of a denaturing step of 94°C
for 15 s, an annealing step of 55°C for 30 s, an extension step of 68°C for 3min 30 s,
followed by a final extension of 68°C for 10 min. The product of the 1st round PCR was
subsequently used as a template in the 2nd round PCR under same conditions but with a
total of 45 cycles. Amplicons were inspected using similar methods to gp41, with a target
amplicon size of 3kb. Sequences that contained stop codons, large deletions, or mixed
bases were removed from further analysis.

Phylogenetic analyses
Sequences from each participant were aligned using Geneious 11.0.3 and alignments
were adjusted as necessary by visual inspection. Maximum likelihood phylograms for
each participant were inferred using PhyML 3.0, which jointly estimates the tree and the
parameters of the evolutionary model. Within-participant alignments were aligned
sequentially using Geneious 11.0.3. Pairwise diversity estimates were performed by
DIVEIN1047. To determine the clonality of rebound viremia, sequences were analyzed by
modified version of a previously described model of neutral virus evolution3,46, which
assumes virus undergoes rapid expansion without selection. Under this model, lowdiversity sequence lineages display a star-like phylogeny and a Poisson distribution of
mutations, coalesce to an unambiguous founder sequence enabling estimates of time
from a MRCA46,48. We estimate that two weeks of ATI is sufficient for cART washout, and
that first detectable rebound arises from multiple pre-existing HIV-1 variants archived in
latently infected cells. Rebound viruses forming identical or low diversity lineages with
<3bp mutations in HIV-1 env or <1bp mutation in gp41 (maximum number of mutations
used to distinguish between pre-existing and de novo mutations using the in vivo
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evolution rate of HIV-1: 4.1x1.7x10-3 per base per cell)49 are categorized as a clonal
lineage, derived from the clonal expansion of a single recrudescent virus. All sequences
will be deposited in GenBank (accession numbers to be determined).

Env cloning and pseudovirus titering
Select env sequences from first detectable rebound were molecularly cloned for the
production of pseudovirus and phenotypic analyses as described previously33. Correctly
sized amplicons identified by gel electrophoresis were gel-purified by using the QIAquick
gel purification kit according to the recommendations of the manufacturer (Qiagen),
ligated into the pcDNA 3.1 Zeo (+) Expression Vector (Invitrogen) and transformed into
NEB 5-alpha Competent E. coli. 100 µl of transformed bacteria were plated on LB agar
plates supplemented with 50 µg/ml ampicillin and cultured at 37°C for 24 hours. Single
colonies were selected and grown overnight in liquid LB broth at 37°C with 250 rpm
shaking followed by plasmid isolation. Finally, each molecular clone was sequenceconfirmed to be identical to the previously determined env sequence of the amplicon.
Pseudovirus was prepared by transfecting overnight cultured 0.5x106 293T cells in
9.4cm2 tissue culture dishes with 500 ng of rev/env expression plasmid and 500ng of
pSG3Δenv Backbone using Fugene 6 (Roche Applied Science, Indianapolis, IN) in
Dulbecco’s Modified Eagle Medium (DMEM). Culture supernatants were harvested 48
hours after transfection, cleared of cellular debris by 0.45-micron filter and stored in
aliquots at -80°C. Pseudoviruses were titrated on TZM-bl reporter cells (8129; NIH AIDS
Research and Reference Reagent Program), which contain a Tat-inducible 11 luciferase
and a β-galactosidase gene expression cassette. Infectious titers were measured on 24well plates based on β-galactosidase production, representing the number of infection
events per µL of virus stock (IU/µL) as described previously4,33.
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Neutralization assays
Virus neutralization by plasma was assessed on TZM-bl cells as described
previously4,33,50. TZM-bl cells were seeded at 1 × 104 cells per well and cultured in 96well plates overnight. Virus stock dilutions were made to final concentrations in
Dulbecco's modified Eagle's medium (DMEM) containing 6% fetal bovine serum (FBS)
and 40 μg/ml DEAE-dextran (Sigma-Aldrich, St. Louis, MO) to achieve 2,000 IU/well.
Viruses with low numbers of IU per microliter were added at no less than 1,500 IU/well.
Equal-volume virus dilutions and 5-fold serially diluted sera or MAbs were mixed and
incubated at 37°C for 1 h. Supernatants were then removed, and 80 μl of these mixtures
was added. Medium-only and virus-only control wells were included as background and
100% infectivity, respectively. Luciferase activity was measured after 48 h of incubation
at 37°C by using Bright-Glo according to the manufacturer's instructions (Promega). All
assays were done in triplicate in each of at least two independent experiments. To
calculate the concentration of antibody that neutralized 50% of virus infection (50%
inhibitory concentration [IC50]), the antibody dose-response curves were fit with a fourparameter logistic equation by using Prism 7.0 (GraphPad Software, Inc., San Diego,
CA). When 50% neutralization was not achieved at the highest concentration of plasma
or antibody used, the IC50 was recorded as being higher than the highest concentration
used.

Isolation and quantification of pre-ATI IgG
Approximately 1ml of pre-ATI plasma samples from S53 and S60 were collected at 6
and 8 weeks before ATI and heat inactivated at 56° for 45 minutes. Purified IgG was
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isolated using the rProtein A/Protein G GraviTrap (GE Healthcare Life Sciences 289852-56) following manufacturer’s instructions. Isolated IgG concentrations were
determined using the BCA protein assay kit (Pierce) using manufacturer’s instructions
and analyzed with the following microplate procedure: 10 µl of the standard solutions
from Bovine Gamma Globulin Standard Pre-Diluted Set (Pierce) was pipetted into a 96Well polystyrene plate (Pierce) in replicates, water was used as a blank. The protein was
diluted in PBS to make 25 µl dilutions ranging from 1:10 – 1:30. 10 µl of each dilution
mixture was added to the plate in replicates. 200 µl of the Working Reagent (50 parts of
BCA Reagent A to one part of BCA Reagent B) was added to all the wells containing
protein and standard solution. The plate was covered in plastic, mixed thoroughly on a
plate shaker for 30 seconds, and placed in a 37° incubator. After 30 minutes, the plate
was removed from the incubator and allowed to cool for 10 minutes at room
temperature. The absorbance was measured at 562 nm on a plate reader. A standard
curve was prepared by plotting the average Blank-corrected 562 nm measurement for
each prediluted standard vs. its concentration in μg/mL. Final IgG concentrations per ml
were determined using the standard curve. Mean IgG collected was 22.3mg/ml per
participant. In order to recapitulate the amount of human IgG circulating in the plasma in
HIV-1 infected, cART-treated individuals (29577+/-607 mg/dl)47, we diluted total collected
IgG to 20 mg/ml followed by a 1:20 top dilution (1000 µg/ml) and 4-fold serial dilutions for
neutralization analyses. All assays were done in triplicate in each of at least two
independent experiments.

Statistical methods.
Statistical analyses. Given the small sample size (n=11, n=2), non-parametric tests were
used for all comparisons. The test for within-person change from persisting to cleared
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lineages were carried out by Wilcoxon rank sum test. Spearman correlation testing was
used to test the association between measures. Analyses were conducted in Statistical
Analysis System (SAS), version 9.4.
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CHAPTER 3

Effect of HIV Antibody VRC01 on Viral Rebound After Treatment Interruption
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Abstract
Significant advances in the field of single-cell antibody cloning have led to the discovery
of multiple exceptionally potent broadly neutralizing antibodies (bNAbs) in HIV infected
individuals. BNAbs target conserved regions of the HIV-1 Env glycoprotein to neutralize
the majority of diverse HIV strains, making these monoclonal antibodies an exciting new
addition to potential HIV cure strategies currently being tested in humans. While a recent
clinical trial of a single bNAb infusion was found to be safe and effective at reducing HIV1 rebound viremia in the majority of infected patients, variability in the diversity and
kinetics of rebounding viruses suggests bNAb monotherapy may affect individuals
differently1. Elucidating the within-host dynamics of HIV during passive bNAb infusion
and ATI will be a critical step in informing the development of future treatment strategies
for HIV-1 eradication.

In this study, I determine the within-host viral dynamics of HIV during passive bNAb
infusion in the AIDS Clinical Trials Group study A5340 taking place at the University of
Pennsylvania. The CD4 binding site (CD4 bs) bNAb, VRC01, was administered
intravenously to 15 chronically infected individuals, where recrudescent viremia during
bNAb infusion represented viruses that were able to “breakthrough” VRC01 intervention
and were used as a metric of therapeutic effect. Using archived plasma samples, I
performed genotypic and phenotypic analyses on viruses from pre-cART and rebound
time points using SGS, molecular cloning, and neutralization assays. Through
phylogenetic analyses, I identified multiple participants with VRC01-mediated restriction
of viral lineages that emerged from latency. Phenotypic analyses through Env cloning
confirmed the prevalence of clinically significant pre-existing resistance to VRC01, which

65

correlated with viral rebound kinetics. This assessment of VRC01-resistant viruses
breaking through ATI and VRC01 infusion highlight future challenges of monotherapy
with bNAbs. The degree of baseline VRC01 resistance was striking, and confirms the
need for more broad, potent bNAbs that are able to target a diversity of viral epitopes.
Additionally, this work emphasizes a need for standardized clinical assays that can
accurately assess for low frequencies of resistant viruses before participants undergo
bNAb infusion and ATI.
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Introduction
Advances in B cell cloning have led to the isolation of HIV-specific broadly neutralizing
antibodies (bNAbs) capable of potently neutralizing cell-free viruses from multiple clades
circulating worldwide1-8. Combinatorial infusion of bNAbs targeting various epitopes on
the Env glycoprotein greatly contribute to viremic suppression in humanized mouse and
rhesus macaque models of HIV-1 infection9. Additionally, macaques treated with bNAb
cocktails show reductions in measured proviral DNA and increases in HIV-specific
cellular immune responses, suggesting that bNAb infusion may directly or indirectly
target cell-associated virus within the latent reservoir and “boost” adaptive immune
responses10-11. In the parent AIDS Clinical Trials Group Study A5340 being conducted at
the University of Pennsylvania, we will determine whether VRC01, a bNAb targeting the
CD4 receptor binding site (CD4bs) of the HIV envelop glycoprotein, can suppress viral
rebound in chronically infected humans during brief analytical treatment interruption
(ATI) of ART (see Figure 1 for A5340 schema).

VRC01 has been shown to neutralize approximately 90% of 190 group M HIV Env
pseudoviruses with a mean 50% inhibitory concentration (IC50) of 0.33 µg per milliliter.
Recent studies implementing passive bNAb immunotherapy in mice and macaques
suggest that in addition to potent viral suppression, bNAbs may also enhance host
immune responses and reduce levels of proviral DNA across compartments12-15. These
findings have raised enthusiasm for bNAb’s potential ability to eradicate HIV, but need to
be confirmed in human studies. The benefits of HIV-1 specific bNAbs over cART include
their ability to be delivered as long-acting agents through Fc engineering6 or vectored
delivery15,

16

.

Additionally, unlike cART, the Fc portion of bNAbs enable possible
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engagement with host immune cells and contribute to the killing of infected cells and
mediate clearance of the persistent viral reservoir 4, 17, 18, 19.

Previous clinical trials in humans have shown that VRC01 administration is safe and well
tolerated in uninfected individuals, as well as viremic or cART-suppressed individuals22,
24

. In the majority of viremic individuals, a 1.1 to 1.8 log10 decrease in plasma viral loads

were observed shortly after VRC01 infusion. Interestingly, further analysis showed that
25% of participants did not achieve viral suppression due to a minor pool of circulating
VRC01-resistant strains.

Other studies assessing VRC01 sensitivity in HIV-1 viral

isolates from cART-suppressed participants show that while some participants harbor a
low frequency of VRC01-resistent replication competent viruses within the viral reservoir,
the majority of cART-suppressed participants contain latent viruses that are sensitive to
VRC01 in vitro. The identification of VRC01-resistant variants also raised the question
of whether these minority resistant variants would emerge during VRC01 infusion and
ATI. My goal in this study was to determine if passive infusion of VRC01 would restrict
the clonality and phenotype of viruses rebounding from the latent reservoir. These
studies highlight the complexity of viral rebound dynamics during high levels of
circulating bNAbs and further inform our understanding of archived resistance in
chronically infected participants.

Results
Participant demographics
We enrolled 14 participants, all of whom were male, with a median age 38 years
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(interquartile range, 34-44), 7 (50%) African American and 7 (50%) Caucasian. CD4 Tcell count at enrollment was 896 cells per cubic millimeter (interquartile range, 579 to
1053) and a median duration from the initiation of cART to study entry of 4.7 years
(interquartile range, 3.8-6.0) and 10 (71%) were on INSTI and 4 (29%) on PI cART
regimens (see table 3.1 for summary of baseline characteristics). One participant was
excluded from the analyses of time to viral rebound because he discontinued ART
before the administration of VRC01. All remaining participants completed the three
infusions VRC01 per protocol, with only one serious adverse event reported that was not
related to VRC01. The safety and tolerability profile of VRC01 are consistent with
separate, larger ongoing clinical trials of the same product. All participants were rapidly
suppressed with their original cART regimen upon two consecutive confirmations of
plasma viral rebound at 500 copies per milliliter. The median time of cART cessation
was 6 weeks (range, 3 to 13) and the median time from the first detectable HIV RNA
level of 200 copies per milliliter or more to the first suppressed HIV level of less than 200
copies per milliliter after ART reinitiation was 6 weeks (range, 3 to 14). Throughout ATI,
no participant had measurable CD4 T cell counts below 350 cell per milliliter. Additional
participant demographics and clinical characteristics can be found in Table 3.1.

Treatment procedures, study objectives, and study outcomes
In step 1 of the A5340 trial, 14 participants received up to three doses of VRC01 (40 mg
per kilogram of body weight administered intravenously) at 3-week intervals (Fig. 3.1).
Participants then discontinued cART after the first VRC01 infusion and were followed
weekly until HIV RNA levels reached ≥200 copies/ml followed by a confirmation level of

69

≥1,000 copies/ml, or three consecutive measurements of ≥200 copies/ml, or until they
had confirmed CD4 T cell counts of <350 cells/mm3. Upon confirmation of viral rebound
or decreased CD4 T cells, participants entered step 2 of A5340, at which point cART
was reinitiated and participants were followed until plasma viral loads were
<50copies/ml. The objectives of this clinical study was to assess the safety and sideeffect profile of VRC01 infusions in cART-suppressed individuals, and to estimate the
proportion of participants with viral rebound in the presence of high plasma
concentrations of VRC01 at 8 weeks of ATI. Secondary objectives included the
frequency of rebound viremia at 4 weeks as well as the evaluation of the
pharmacokinetic characteristics of VRC01. In this study, the key exploratory objectives
were the frequency of anti-idiotype antibodies against VRC01 as well as the genetic and
phenotypic characterization of the rebound virus. With 13 participants with evaluable
data, we had 95% power to detect a difference of 40 percentage points14 at a two-sided
alpha level of 0.10. Of the 14 enrolled participants, 13 completed the clinical trial with
evaluable data.

Time to viral rebound
Interestingly, while measured plasma VRC01 were above 50µg/ml (median 175, range
68-1,494) (Fig. 3.2) 12 of 13 participants did not experience durable suppression of
plasma viremia for more than 8 weeks. The median time to rebound was 4 weeks which
is a small delay in viral rebound kinetics compared to kinetics observed in historical
controls from previous ACTG studies; 38% of A5340 participants remain virally
suppressed at week 4 versus 13% of historical controls (P = 0.04 by a two-sided Fisher’s
exact test) and 8% and 3%, respectively, were suppressed at week 8 (P = 0.44 by a two-
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sided Fisher’s exact test) (Fig. 3.3). Participant A07 had prolonged viral suppression
and detectable viremia at week 11 of ATI, when plasma levels of VRC01 waned to 25µg
per milliliter. Participant A11 was excluded from evaluation due to a premature pause in
cART, causing detectable plasma viremia at the time of VRC01 infusion. Throughout the
course of the trial, no anti-idiotype antibodies were identified in any of the participants.

Sequence evidence of VRC01-mediated virus restriction
To characterize the genotype of rebounding viral populations, I generated cDNA from
extracted viral RNA from samples collected from pre-cART plasma (8 participants) as
well as plasma collected from the first and second weeks of detectable viremia (13
participants). Next, nested PCR HIV-1 gp160 primers were used to amplify full-length
env sequences from each participant and single-genome sequencing methods were
used to determine the genome of individual pre-cART and/or rebound sequences.
These sequences were analyzed together in a maximum likelihood (ML) phylogenetic
tree and showed independent clustering, confirming the relatedness of pre-cART and
rebound viruses (Fig. 3.4).

Independent studies (including the ATI clinical trial discussed in Chapter 2 of this thesis)
that assessed the diversity of the rebounding viral quasispecies have shown that in the
absence of therapeutic intervention, first detectable viral rebound is polyclonal due to the
activation of multiple latently infected cells27-29. In this study, I assessed for genetic
evidence of VRC01-mediated viral restriction by comparing the number of genetically
distinct virus populations compared to historical controls. In 3 of 12 participants (25%)
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who rebounded in the presence of high plasma concentrations of VRC01, sequence
evidence suggested VRC01-mediated restriction of viral rebound. In participant A04,
A02 (Fig. 3.4), and A12 (Fig. 3.5) pre-cART plasma virus formed characteristic
unstructured phylogenetic trees characteristic of chronic HIV infection. Rebound
lineages from these participants, however, clustered into low-diversity lineages of nearly
identical sequences and conformed to a strict model of neutral virus evolution, where the
genetic distance of the most recent common ancestor of these low-diversity rebound
lineages suggests recent clonal expansion of a single virus. The remaining 9 of 12
participants (75%) had polyclonal rebound similar to what is observed in historical
analytic treatment interruption without resistance. Rebound viruses from participant A05
clustered into multiple genetically distinct rebound lineages that align throughout the preART virus phylogeny, while Participant A03 had rebound sequences that clustered
unevenly

within

the

pre-ART

virus

population,

supporting

sequence

compartmentalization (Fig. 3.4). In participant A07, first detectable rebound was
observed at week 11 with lower plasma levels of VRC01 (Fig. 3.4). I observed two
closely related rebound lineages in this participant that were distinct from the pre-cART
viral quasispecies.

Further, we identified specific amino acid changes within the VRC01 antibody-binding
site with the use of neutralization-based epitope prediction identified in or near the
VRC01 epitope (located within the V5 loop and the CD4-binding loop). These data
suggest that VRC01 is mediating selective pressure on rebounding virus (Fig. 3.7)
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Selection for VRC01-Resistant Rebounding Viruses
Next, I determined the role of resistance to VRC01 at viral rebound in the presence of
high VRC01 concentrations. I hypothesized that early viral rebound and viral restriction
of select lineages from latency was caused by pre-existing resistant variants emerging
from the latent reservoir. To test this, I cloned select pre-cART and rebound envs from
throughout the participant’s viral quasispecies and expressed these envs via
pseudoviruses to determine env VRC01 sensitivity in standardized in vitro HIV-1
neutralization assays. All participants who had rapid viral rebound with high
concentrations of circulating VRC01 also contained rebound envs with IC50
neutralization titers greater than 1 µg/ml (median 4.55 µg/ml, range 1.1 µg/ml- >50
µg/ml), conferring moderate resistance to VRC015, 32, 33. I also compared pre-cART and
rebound Envs in the 8 participants who contained sequences from both time points. I
observed a trend towards increased VRC01-resistance at rebound (mean increase by a
factor of 3.79, P = 0.004 by a two-sided random-effects model). Overall, participants in
A5340 had greater baseline resistance to VRC01 in comparison to previous HIV-1
panels (p=0.003, two-sided Wilcoxon rank sum test)5. Summaries of the IC50 titers of
pre-cART and rebound viruses from each participant can be found in Fig. 3.4 and Fig.
3.6.
When comparing rebound kinetics and pre-cART resistance to VRC01 in participants
with available plasma samples, I also found that the timing of viral rebound was
associated with increased pre-existing VRC01 resistance. Participants A02 and A07,
who had the longest delay in viral rebound (8 and 11 weeks respectively), also had a
mean pre-cART IC50s of <1µg/ml with the emergence of VRC01 sensitive monoclonal
or oligoclonal viral lineages.

In contrast, participants A05, A06, and A09 harbored
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multiple VRC01-resistant pre-cART variants. Infusion of VRC01 in these participants
was followed by the rapid emergence of polyclonal rebound viruses that were highly
resistant to VRC01. Interestingly, in participants with a range of pre-cART VRC01
sensitivities (Participant A03, A04 and A12), I found that while rebound also occurred
soon after ATI (range, 2-6 weeks), sequence analyses of rebound variants show
monoclonal or compartmentalized rebound.
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Tables

Table 3.1 Characteristics of the participants at baseline for ACTG Clinical Trial
A5340, Step 1. From N Engl J Med., Bar et al., Effect of HIV Antibody VRC01 on Viral
Rebound after Treatment Interruption, 375(21). Copyright © (2016) Massachusetts
Medical Society. Reprinted with permission.
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Figures

Figure 3.1 A5340 Step 1 Study Schema. The A5340 trial had two steps. In step 1,
participants received an intravenous infusion of VRC01 (at a dose of 40 mg per kilogram
of body weight) (triangles) 1 week before and 2 and 5 weeks after discontinuation of
antiretroviral therapy (ART). ART was discontinued 1 week after the first VRC01
infusion. The treatment interruption was open-ended, and participants were monitored
weekly until viral rebound. On confirmed plasma viral rebound, participants entered step
2 and ART was reinitiated. Participants were then followed until plasma viremia
decreased below 50 copies per milliliter. HIV env sequencing (gray circles) was
performed with the use of plasma samples obtained before the initiation of ART and after
viral rebound. From N Engl J Med., Bar et al., Effect of HIV Antibody VRC01 on Viral
Rebound after Treatment Interruption, 375(21). Copyright © (2016) Massachusetts
Medical Society. Reprinted with permission.
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Figure 3.2 Early viral rebound despite high plasma levels of VRC01. A. Plasma
concentrations of VRC01 for all participants are plotted against time of ATI. All
participants maintained plasma levels of VRC01 greater than 50 μg/ml for more than 8
weeks and 12/13 participants experienced viral rebound with these levels. Solid circles
indicate measured levels before viral rebound; open circles were obtained after viral
rebound. The blue diamonds indicate levels of VRC01 at the time point of first detectable
viremia. Modeling of VRC01 pharmacokinetics shown by black line. From N Engl J Med.,
Bar et al., Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption,
375(21). Copyright © (2016) Massachusetts Medical Society. Reprinted with permission.
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Figure 3.3 Plasma viremia and levels of VRC01 in trial participants after
discontinuation of ART. Panel A shows the plasma viremia of partiipants in the A5340
trial after initiation of ATI. Gray dotted line indicated limit of detection of the assay (HIV
RNA level, 20 copies per milliliter). Panel B shows the plasma viremia of NIH tial
participants after ATI. The gray dotted line indicates the limit of detection in the assay
(HIV RNA level, 40 copies per millileter). Panel C shows the Kaplan-Meier curve of
plasma viral suppression (<200 copies per milliliter) after VRC01 administration and ATI
in A5340 and NIH trial participants as compared with historical participants in AIDS
Clinical Trials Group (ACTG) trials who underwent ATI without other immunotherapeutic
interventions. Panel D shows in vivo plasma levels of VRC01 at first detectable viremia.
The limit of detection of VRC01 was less than 0.98 µg per milliliter. From N Engl J Med.,
Bar et al., Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption,
375(21). Copyright © (2016) Massachusetts Medical Society. Reprinted with permission.
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Figure 3.4 VRC01 neutralization titers before ART and during viral rebound.
Panels A through D show maximum likelihood phylogenetic trees of single-genome
sequencing–derived env sequences from pre-ART and rebound plasma virus and
neutralization titers to VRC01 from four participants. Participants A04, A05, and A03 had
early viral rebound despite high levels of VRC01; Participant A07 had delayed rebound
with lower plasma VRC01 levels. Black rectangles indicate pre-ART plasma env
sequences, and red and orange rectangles indicate the env sequences from the first and
second weeks of detectable viremia. The scale bar indicates genetic distance. Fifty
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percent inhibitory concentration (IC50) neutralization titers are shown to the side of each
tree aligned to the specific envelope glycoprotein that was cloned and tested for
phenotypic features. Asterisks indicate bootstrap support of greater than 80%. As shown
in Panel A, Participant A04 had monoclonal rebound with VRC01-resistant virus. As
shown in Panel B, Participant A05 had polyclonal rebound with VRC01-resistant virus.
As shown in Panel C, Participant A03 had polyclonal rebound with VRC01-resistant
virus. Multiple rebound lineages arise clustered within one area of the phylogeny.
Sequences from Participant A03 were tested for clustering; Slatkin–Maddison and
Hudson’s “nearest neighbor” tests support sequence compartmentalization (P<0.001
and P=0.004, respectively). As shown in Panel D, Participant A07 had polyclonal
rebound of VRC01-sensitive virus. As shown in Panels E and F, pre-ART and rebound
Env pseudotyped virus from the eight participants with available samples were
compared for changes in neutralization sensitivity by IC50(truncated at 25 μg per
milliliter) (Panel E) and 80% inhibitory concentration (IC80) (truncated at 50 μg per
milliliter) (Panel F) with the use of multilevel random-effects models (random intercept
and slope) to account for multiple clones per participant at each time point. A two-sided
P value for the estimated difference in pre-ART and rebound resistance was calculated.
Mean titers are shown for pre-ART virus on the left and rebound virus on the right. From
N Engl J Med., Bar et al., Effect of HIV Antibody VRC01 on Viral Rebound after
Treatment Interruption, 375(21). Copyright © (2016) Massachusetts Medical Society.
Reprinted with permission.
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Figure 3.5 Maximum Likelihood (ML) phylogenetic trees of individual participants.
Maximum likelihood phylogenetic trees of gp160 env sequences from participants not
displayed in Figure 3 are shown, except Participant 11, whose sequences were not
evaluated due to early discontinuation of ART. Pre-ART sequences are shown in black,
rebound sequences from weeks 1 and 2 of detectable viremia are shown in red and
orange, respectively. Genetic distance scale bars are shown for each tree and bootstrap
support >70% is shown with asterisks. Pre-ART plasma was not available in participants
A01, A08, A10, A13, A14. For participant A09, only the Subtype B sequences are
displayed here to allow for assessment of the relatively smaller genetic distances
between the pre ART and rebound subtype B sequences. Monoclonal rebound lineages
are seen in participants A02 and A12. Polyclonal lineages are seen in participants A01,
A06, A08, A09, A10, A13, and A14. From N Engl J Med., Bar et al., Effect of HIV
Antibody VRC01 on Viral Rebound after Treatment Interruption, 375(21). Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.
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Figure 3.6 VRC01-resistance of pre-cART and rebound viruses.
Pre-ART and rebound Envs from the eight participants with available samples were
compared for changes in neutralization sensitivity by IC50 (truncated at 25 μg/mL), IC80
(truncated at 50 μg/mL) and MPI. Individual Env titers were plotted laterally, while the
mean titers per participant were compared between time points centrally. A. By IC50,
there was a 3.44 fold increase (two-sided random-effects model p value=0.006). B. By
IC80, there was a 3.79 fold increase (two-sided random-effects model p value of 0.004).
C. No change seen in MPI. D. There was a statistically non-significant trend towards
increased resistance comparing the Pre-ART IC50 titers for the eight A5340 participants
(represented as mean of each participant’s individual Envs) to the 49 subtype B Envs
reported in the 2010 report initially characterizing VRC0125, two-sided random-effects
model p=0.13. From N Engl J Med., Bar et al., Effect of HIV Antibody VRC01 on Viral
Rebound after Treatment Interruption, 375(21). Copyright © (2016) Massachusetts
Medical Society. Reprinted with permission.
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Figure 3.7 VRC01 antibody footprint sequence changes from pre-cART to
rebound.
To analyze changes in the predicted VRC01 antibody binding regions between pre-ART
and rebound virus populations, modified longitudinal logo plots were generated with the
Longitudinal Antigenic Sequences and Sites from Intra-host Evolution (LASSIE) tool16.
The VRC01 binding footprint was represented by Env residues in Loop D, CD4 binding
loop, β20/β21 regions, and the base of V5 that are known VRC01 contact residues17. All
sequences were compared to the consensus of the rebound viruses, which is displayed
as color-coded, bold letters in the second line. The top line shows amino acid differences
in the pre-ART sequences from the rebound consensus. The consensus was generated
as a majority-rule consensus using sequences from the earliest time point post-rebound.
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Residues were colored as follows: acidic residues (ED) in red, basic residues (HKR) in
dark blue, asparagines within N-linked glycosylation sequons (NXS/T, depicted as an
“O”) in cyan, and all other amino acids in black. Gaps are treated as characters. Several
participants, including participants A03 and A04, show substantial changes in the
binding footprint between the pre-ART and rebound sequences, suggesting selection for
a minor variant to arise in rebound. Other participants show minimal changes in the
binding footprint. Between week 1 and 2 of rebound, minimal changes are seen within
the VRC01 binding footprint. From N Engl J Med., Bar et al., Effect of HIV Antibody
VRC01 on Viral Rebound after Treatment Interruption, 375(21). Copyright © (2016)
Massachusetts Medical Society. Reprinted with permission.
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Discussion
Passive infusions of CD4bs bNAbs have recently entered the clinical trial pipeline and
have shown significant and prolonged viral load reduction in the majority of viremic
participants and are now being tested in ATI trials to determine their curative capacity1.
In some individuals, however, bNAb resistant variants prevented successful viral
suppression24. These data suggest either that replicating autologous viruses may
undergo rapid viral escape during passive infusion, or viruses harbor pre-existing
mutations that confer bNAb resistance. In the A5340 clinical trial, I evaluated the effects
of VRC01 infusion in the setting of ATI in 13 chronically infected, cART suppressed
participants. I hypothesized that chronically infected cART-suppressed participants
would harbor a minority population of pre-existing resistant HIV-1 in the viral reservoir,
which would decrease the time to first detectable rebound and restrict the clonality of the
rebound viral quasispecies. In this study, I used SGS methods and phenotypic analyses
of pre-cART and rebound plasma viruses to identify mechanisms that determine viral
rebound dynamics during VRC01 infusion.

Multiple VRC01 infusions were found to be safe and well tolerated, with high levels of
circulating VRC01 in the plasma. Despite this observation, only a modest delay in the
time to viral rebound was observed compared to historical controls, and the majority of
participants rebounded during high levels of circulating VRC01 (>50µg/ml). Sequence
analyses of pre-cART and rebound viruses from 8 participants show that VRC01 can
restrict the clonality of the emerging rebound population. This was specifically observed
in participants with a range of VRC01 sensitivities in pre-cART plasma. During VRC01
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infusion and ATI, these participants had monoclonal or oligoclonal viral populations that
established viral rebound.

In contrast, participants with several highly resistant pre-

cART viruses, polyclonal rebound populations emerged during rebound. While de novo
generation of VRC01 resistance cannot be completely eliminated due to sampling
limitations, the rapid timing of viral rebound in most participants suggests that preexisting resistance to VRC01 is the more likely explanation for rapid viral rebound in this
clinical trial. Together these data suggest that VRC01 exerts significant pressure on
latently infected cells and selects for pre-existing resistant viruses from the reservoir.

It is important to note that sampling of plasma viruses before the initiation of cART only
provides a limited assessment of viruses that could possibly reactivate from the viral
reservoir. Due to the timing of viral rebound in this study, however, it is more likely that
pre-existing resistance drives rapid viral rebound upon ATI and high levels of circulating
VRC01. Additionally, our findings of pre-existing VRC01 resistance driving rapid viral
rebound were also observed in an independent clinical trial NIH 15-I-0140. In the NIH
trial, evidence of selection pressure exerted by VRC01 was identified through sequence
analyses, where specific amino acid changes within VRC01 binding epitopes were
commonly found among pre-cART and rebound viruses. The NIH trial results were
published together with A5340 in Bar et al. NEJM, 2016. Additionally, similar findings
were observed in a recently conducted bNAb clinical trial testing the safety and efficacy
of the more potent CD4 bs bNAb, 3BNC1172 . Four infusions of 3BNC117 delayed viral
rebound for up to 19 weeks in select participants, and further sequence analyses of preinfusion viral isolates and rebound viruses also show that pre-existing resistance
predicts the pattern and timing of viral rebound.
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By assessing VRC01 resistance among multiple pre-cART and rebound viruses, I was
able to highlight the striking prevalence of VRC01 resistance among the majority of
study participants and its relationship to the timing and patterns of viral rebound.
Importantly, our finding highlights that minority variants with pre-existing VRC01
resistance can be archived within the viral reservoir and potentially contribute to viral
rebound upon VRC01 infusion. This finding presents a significant challenge for future
studies testing bNAb efficacy in monotherapy trials, but also highlights the important
observation that bNAb monotherapy can exert modest but significant pressure on
viruses that emerge from the reservoir.

To determine mechanisms of viral rebound during VRC01 infusion and ATI, I performed
sequence analyses of pre-cART and rebound plasma samples and assessed baseline
differences in viral diversity. Through these methods, I found that baseline resistance to
VRC01 is common. The prevalence of VRC01 resistance in pre-cART plasma was
associated with decreased time to viral rebound and the emergence of polyclonal viral
lineages upon treatment interruption. These rebounding lineages were also VRC01resitant. In participants with a diverse pool of VRC01-sensitive and VRC01-resistant
viruses, I observed monoclonal or oligoclonal rebound viruses, suggesting VRC01 is
also able to restrict the clonality of viruses that can emerge from the latent reservoir. In
participants who rebounded beyond week 4, I found monoclonal or oligoclonal
populations emerge. One participant, A07, rebounded at 11 weeks as VRC01 plasma
levels waned significantly. As expected, this participant harbored VRC01 sensitive precART viruses and maintained sensitivity to VRC01 in its oligoclonal rebound population
as well.
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Modest delays in viral rebound in combination with the clonal restriction observed in
some participants suggest that VRC01 exhibits modest pressure on reactivating viruses
from the viral reservoir and is an encouraging finding in the bNAb therapeutic field.
While monotherapy of VRC01 may not be potent enough for successful, long-term
cART-free remission, other studies analyzing the effect of combination bNAb infusions
are promising.

Materials and Methods
Study Design and Oversight
AIDS Clinical Trials Group (ACTG) A5340, was a phase 1, two-step, open-label study of
the safety, tolerability, pharmacokinetics (PK) and antiviral activity of the human
monoclonal antibody, VRC-HIVMAB060-00-AB (VRC01) in HIV-infected individuals
undergoing brief ATI (ClinicalTrials.gov identifier NCT02463227). We enrolled 14 HIV-1
infected men, ages ≥18 years, who had a CD4 T-cell count of ≥450 cells/μL,
undetectable plasma viral load (<50 copies/mL) for at least 24 weeks, CD4 nadir >200
cells/μL, and no known ART during acute or early infection. We excluded participants
receiving non-nucleoside reverse transcriptase inhibitor (NNRTI) based ART due to the
prolonged half-life of those drugs and the potential risk for development of
resistance24,25. Complete inclusion criteria are presented in the Supplement of this
publication.

In Step 1, participants received up to three doses of VRC01 (40mg/kg intravenously) at
three-week intervals (see Figure 1). One week after the first dose of VRC01, participants
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stopped ART and were followed at weekly intervals until they had confirmed CD4 T-cell
count <350 cells/μL or return of HIV-1 viremia, defined as HIV-1 RNA ≥200 copies/ml
followed by a confirmation ≥1000 copies/ml, or three consecutive measurements ≥200
copies/ml. Upon confirmation of viral rebound or CD4 T-cell decline, participants entered
Step 2, when ART was reinitiated and HIV-1 viral load was followed until below 50
copies/ml.

The primary objectives of the study were to assess the safety and tolerability of multiple
doses of VRC01 administered in individuals with well controlled viral replication and to
estimate the proportion of participants with return of viremia in the presence of high
levels of bNAb at 8 weeks of ATI. Secondary objectives were frequency of rebound
viremia at 4 weeks and the evaluation of the PK parameters of the product. Key
exploratory objectives were the frequency of development of antibodies against VRC01
and the genetic and phenotypic characterization of the rebound HIV-1 viruses.

The study was powered for 13 evaluable participants, which provided 95% power to
detect a difference of 40% (i.e., return of viremia by 8 weeks in 50% vs. 90% in historical
controls)21 using a one-sided test with a significance level of 0.05. The time to viral
rebound was compared with historical controls from other treatment interruption trials
conducted by the AIDS Clinical Trials Group (ACTG)21. Details of the control group,
participant monitoring, and laboratory and statistical methods are outlined in the online
supplement.

The study was conducted at two ACTG sites: the University of Pennsylvania and the
University of Alabama Birmingham. All participants provided written informed consent.
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All the authors vouch for the accuracy and completeness of the data and the fidelity of
the study to the protocol.

Study inclusion criteria
In addition to HIV-specific criteria, exclusion criteria included known treatment during
acute infection, previous receipt of a humanized or human mAb, treatment with
systematic glucocorticoids or other immunomodulators, active hepatitis B or C virus
infection, ongoing opportunistic infection(s), history of an AIDS-defining illness, history of
severe allergic reactions, abnormal laboratory values, inadequate venous access, and
weight >115 or <53 kilograms. A plasma or serum specimen before the initiation of ART
was required for at least 8 participants.

VRC01 antibody product
The VRC01 antibody product was manufactured by the NIAID/Vaccine Research Center
(VRC) using recombinant DNA technology in the mammalian Glutamine Synthetase
Gene Expression System in the Chinese hamster ovary (CHO) cell line developed by
Lonza Biologics (Slough, UK). The 40 mg/kg dosing strategy was chosen based on the
observed 14 day half-life in aviremic HIV-infected individuals in prior trials1, 2.

Adverse Events Monitoring
Diagnosis, signs and symptoms, and laboratory results were graded using version 2.0 of
the Division of AIDS (DAIDS) adverse events (AEs) grading table, and assessed for
relationship to VRC01 by the core study team. Post-entry, sites were required to report
all signs and symptoms of grade 2 of higher, as well as all solicited signs and symptoms
that were grade <2 from an infusion report card asking participants about injection site
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pain, redness, swelling and induration, as well as systematic AEs like feeling unwell,
muscle aches, headache and chills during the 7 days after receipt of the antibody. All
diagnoses identified by the ACTG criteria for clinical events and other diseases were
additionally required to be reported. DAIDS AEs grading table described at:
http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx. ACTG criteria
described at http://reprievetrial.org/wp-content/uploads/2014/11/Appendix100.pdf.

Historical ACTG data on control ATI group
There have been six previous ACTG clinical trials that have utilized analytical treatment
interruptions (ATI). A total of 61 participants were on suppressive non-NNRTI ART
started during chronic infection and received no immunologic interventions. At week 4 of
the ATI the proportion of participants with virologic suppression <200 copies/mL was
13% (8/61), and at week 8 it was 3% (2/61) (Fig. 3.3C) For the comparison with
historical controls we used participants in ACTG trials that were receiving non-NNRTIbased regimens because of the prolonged half-life of NNRTIs artificially delayed the
return of viremia.

Power calculations
We planned to enroll 15 participants; all receiving VRC01. We assumed a 15% loss to
follow-up or non-protocol required study treatment discontinuation, to have a total of 13
evaluable participants for planned per-protocol analysis, using the binomial distribution
and the conservative assumption that in the absence of an intervention 90% will have a
return of viremia within 8 weeks of treatment interruption, we had 95% power to detect a
difference of 40% (i.e., return of viremia by 8 weeks in 50%) using a one-sided test with
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a significance level of 0.05. Regarding the assessment of safety, the sample size of 15
VRC01-treated participants would provide a 90% probability of observing a VRC01related AE that would occur in 14% or more of treated participants. After enrollment of
13 evaluable participants for the primary efficacy analysis, recruitment was stopped with
a total of 14 participants receiving VRC01.

Trial outcome analysis
For analysis of time to first confirmed HIV-1 RNA ≥200 copies/ml during the ATI, HIV-1
RNA measurements were binned at the nearest scheduled week. The cumulative
probability of remaining virologically suppressed (i.e. no confirmed HIV-1 RNA ≥200
copies/ml) was calculated by Kaplan-Meier methods, and at 4 and 8 weeks 90%
confidence intervals (CI) were generated using the Clopper-Pearson exact method.
Comparison to historical ACTG data was by the one-sided Fisher’s exact test, and
Spearman’s rank correlation coefficients were calculated to assess the relationship
between pre-ART and study entry variables with time to first confirmed HIV-1 RNA ≥200
copies/ml. For the safety analysis, all participants exposed to VRC01 were included, and
the percentage of participants experiencing a grade 3 or higher AE was calculated along
with a 95% Clopper-Pearson exact CI.

VRC01 plasma concentration measurements and modeling
Quantification of VRC01 concentrations in participant serum and individual participant
noncompartmental PK analysis were performed as previously described2. Briefly, VRC01
serum concentration quantification was performed in 96-well plates on a Beckman
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Biomek–based automation platform using the anti-idiotype mAb 5C9. Pharmacokinetic
data were fit to a two compartment population model using the computer program
NONMEM (version 7.2).

Viral RNA extraction, cDNA synthesis, single genome sequencing (SGS)
SGS enables proportional representation of the complex HIV-1 virus quasispecies with
linkage across the sequenced region with minimal in vitro errors4. Viral RNA extraction,
cDNA synthesis, and SGS were performed to amplify gp41 or gp160 env as previously
described4, 5. Amplicons were directly sequenced and chromatograms were inspected for
evidence of priming from multiple templates or introduction of PCR error in early cycles.

Phylogenetic analyses
Sequences from each participant were aligned using ClustalW6 and alignments were
adjusted as necessary by visual inspection. Regions in within-participant alignments that
could not be unambiguously aligned were removed from subsequent phylogenetic
analyses. Maximum Likelihood (ML) phylograms for each participant were inferred using
PhyML version 37, which jointly estimates the tree and the parameters of the
evolutionary model. Evolutionary model classes for within-participant data sets were
selected using jModelTest version 2.1.47,

8

using the AICc criterion9. Within-participant

alignments were aligned sequentially using ClustalW. Hypervariable regions as defined
in Los Alamos National Laboratory HIV Sequence Database Variable Region
Characteristics webtool (http://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/)
and other regions that could not be unambiguously aligned were removed from the
alignment used for the phylogenetic analysis encompassing all of the sequences.
Pairwise diversity estimates were performed by DIVEIN10. Assessment for phylogenetic
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clustering within individual participant’s sequences was performed by Slatkin-Maddison
and Hudson’s nearest neighbor tests11-13. To determine the clonality of rebound viremia,
sequences were analyzed by a previously described model of neutral virus evolution4, 14,
which assumes virus undergoes rapid expansion without selection. Under this model,
low-diversity sequence lineages display a star-like phylogeny and a Poisson distribution
of mutations, coalesce to an unambiguous founder sequence enabling estimates of time
from a most recent common ancestor (MRCA)4,

14,15

. Pairwise nucleotide Hamming

distances were calculated using code from the Los Alamos National Laboratory HIV
database Variable Region Characteristics webtool (http://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/) and other regions that could not be unambiguously aligned
were removed from the alignment used for the phylogenetic analysis encompassing all
of the sequences (Fig S3). Pairwise diversity estimates were performed by DIVEIN10.
Assessment for phylogenetic clustering within individual participant’s sequences was
performed by Slatkin-Maddison and Hudson’s nearest neighbor tests11-13. To determine
the clonality of rebound viremia, sequences were analyzed by a previously described
model of neutral virus evolution4,

14

, which assumes virus undergoes rapid expansion

without selection. Under this model, low-diversity sequence lineages display a star-like
phylogeny and a Poisson distribution of mutations, coalesce to an unambiguous founder
sequence enabling estimates of time from a most recent common ancestor (MRCA)4,
14,15

. Pairwise nucleotide Hamming distances were calculated using code from the Los

Alamos National Laboratory HIV database Poisson Fitter version 2 tool. In calculating
Hamming distances, gaps were excluded. For rebound virus populations that met these
criteria (p>0.05 in goodness-of-fit to Poisson distribution), recent clonal expansion from a
single virus was interpreted to indicate a single virus rebounded from latency to found
systemic virus replication during rebound. If rebound sequences violated the conditions
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of this model, it was interpreted that more than one virus rebounded from latency to
found rebound viremia. All sequences were deposited in GenBank (accession number:
KX587007-KX587459).

Env gene cloning and pseudovirus production.
Select env sequences from throughout the pre-ART phylogeny and those representing
the consensus sequence of low-diversity rebound lineages were molecularly cloned for
the production of pseudovirus and phenotypic analyses as described previously4,5.
Briefly, to reduce the probability of generating molecular env clones with Taq
polymerase errors, we reamplified from the first-round PCR product under the same
nested PCR conditions but used only 25 cycles. Correctly sized amplicons identified by
gel electrophoresis were gel-purified by using the QIAquick gel purification kit according
to the recommendations of the manufacturer (Qiagen), ligated into the pcDNA3.1
Directional Topo vector (Invitrogen Life Technologies), and transformed into competent
TOP10 E. coli bacteria. Bacteria were plated on LB agar plates supplemented with 100
μg/ml ampicillin and cultured at 25°C for 3 days. Single colonies were selected and
grown overnight in liquid LB broth at 30°C with 225 rpm shaking followed by plasmid
isolation. Finally, each molecular clone was sequence-confirmed to be identical to the
previously determined env sequence of the plasma env amplicon. Pseudovirus was
prepared by transfecting overnight cultured 3x106 293T cells in 10cm2 tissue culture
dishes with 4 μg of rev/env expression plasmid and 4 μg of HIV-1 backbone: using
Fugene 6 (Roche Applied Science, Indianapolis, IN). Pseudovirus containing culture
supernatants were harvested 2 days after transfection, cleared of cellular debris by lowspeed centrifugation and stored in aliquots at -80°C. Viruses were titrated on TZM-bl
reporter cells (8129; NIH AIDS Research and Reference Reagent Program), which
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contain a Tat-inducible luciferase and a β-galactosidase gene expression cassette.
Infectious titers were measured on 24-well plates based on β-galactosidase production,
representing the number of infection events per μL of virus stock (IU/μL) as described
previously18.

Neutralization assays
Virus neutralization by VRC01 was assessed on TZM-bl cells as described previously18.
TZM-bl cells were seeded at 1x104 per well and cultured in 96-well plates overnight.
Virus stocks dilutions were made to final concentrations of DMEM containing 6% FBS
and 40 μg/mL DEAE dextran (Sigma-Aldrich, St. Louis, MO) to achieve 2000 IU/well.
Equal volume virus dilutions and two to five-fold serially diluted mAbs were mixed and
incubated at 37°C for 1 h. Supernatants were then removed and 80 μL of these mixtures
were added. Media-only and virus-only control wells were included as background and
100% infectivity, respectively. Luciferase activity was measured after 48 h incubation in
37°C using Bright-Glo per the manufacturer’s instructions (Promega). All assays were
done in triplicate in each of at least two independent experiments. To calculate the
concentration of antibody that neutralized 50% (IC50), and 80% (IC80), of virus infection
the antibody dose-response curves were fit with a four parameter logistic regression
equation using Prism 5.0 (GraphPad Software Inc. San Diego, CA). When 50% or 80%
neutralization was not achieved at the 50 μg/ml concentration of VRC01, the IC50 or
IC80 was recorded as 50 μg/ml. Maximal percent inhibition was calculated by
determining the change in infectivity at 50 μg/ml.
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VRC01 neutralization resistance analysis
For comparison of pre-ART and rebound VRC01 resistance by cloned Envs, multilevel
random effects models (random intercept and slope) were fitted to account for multiple
clones per participant at each time-point, and a one-sided p-value for the estimated
difference in pre-ART and rebound resistance was calculated. Analysis was performed
on the log10 scale for IC50 and IC80. For comparison of pre-ART IC50 to an historical
subtype B panel, we used a one-sided exact Wilcoxon rank-sum test to compare the
mean pre-ART log10 IC50 in A5340 to the historical subtype B panel. For analysis, IC50
values were truncated at 25 µg/ml and IC80 values were truncated at 50µg/ml. Analyses
were performed in SAS version 9.4. The historical subtype B panel IC50 values were
obtained in a methodologically similar assay performed in a different laboratory19.
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CHAPTER 4

HIV-1 Latent Reservoir Size and Diversity are Stable Following Brief Treatment
Interruption
This work was published in the following publication:
Salantes DB, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, Li JZ, Tressler RL, Koup
RA, Hoxie J, Abdel-Mohsen M, Sherrill-Mix S, McCormick K, Overton ET, Bushman FD,
Learn GH, Siliciano RF, Siliciano JM, Tebas P, Bar KJ. Journal of Clinical Investigation.
2018. Pii: 120194. doi: 10.1172/JCI120194.
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Abstract
Analytical treatment interruption of cART in HIV-infected individuals is an important
component of HIV-1 cure strategy clinical trials. While brief, closely monitored ATIs are
generally considered to be clinically safe1,2, the effect of transient rebound viremia on the
size and composition of the latent reservoir is unknown. In the previously described
ACTG clinical trial A5340 (presented in Chapter 3 of this thesis), the safety and
tolerability of passively infused CD4 bs bNAb, VRC01, was tested under ATI conditions
in chronically infected participants. Only a modest delay in viral rebound was observed in
the majority of participants compared to ATI studies without immunotherapeutic
intervention. Phenotypic and genotypic analyses of available pre-cART viruses from
these participants identified a high prevalence of pre-existing VRC01 resistance, which
was associated with viral rebound kinetics. Nine participants underwent leukapheresis
prior to ATI and six months after rapid re-suppression of plasma viremia with cART. In
this study, I applied quantitative and qualitative analyses on archived leukapheresis and
plasma samples collected prior to, during and after ATI in order to determine the effect of
ATI on the size and composition of the latent reservoir. Additionally, through SGS
methods, I also identified large, clonally expanded viruses from Quantitative Viral
Outgrowth Assays (QVOA) and genetically intact proviruses in resting CD4 T cells,
though these expanded clones fail to accurately predict viruses that reactivate in vivo.
Taken together, these results demonstrate that brief ATI with transient viremia does not
substantially impact the diversity of the peripheral viral reservoir, though the discordance
between large, clonally expanded lineages identified by QVOA and proviral DNA
sequencing and rebounding viruses highlight the challenges in using current latent
reservoir assays to accurately predict viruses that will reactivate in vivo.
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Introduction
Successful introduction of combination antiretroviral therapy (cART) in HIV-1 infected
individuals can lead to rapid suppression of plasma viremia, resulting in a dramatic
decline in HIV-associated morbidity and mortality. Despite effective cART, HIV persists
primarily in long-lived resting memory CD4+ T cells and latently infected cells remain
stable with a half-life of approximately 44 months3–9. The slow decay of the viral reservoir
prevents HIV eradication with cART alone. Additionally, once cART is removed, multiple
latently infected cells can contribute to recrudescence of plasma viremia10–16. These
infected cells are the target of curative strategies aiming to achieve cART-free remission
and complete eradication of the latent reservoir. However, in the absence of nonviral
biomarkers to accurately identify changes in the size or composition of the reservoir,
analytical treatment interruptions (ATI) of cART are required to determine efficacy of the
novel therapeutic strategy17,18. Brief ATIs have recently been shown to be well-tolerated
in infected participants and have been a useful tool in identifying the genotypic and
phenotypic characteristics of viruses that “break-through” therapeutic intervention13.
Additionally, plasma viremia observed during ATIs interruption is rapidly suppressed
upon re-initiation of the participant’s original cART regimen.

The effect of transient

viremia on the latent reservoir during ATI, however, is unknown. In this study, I
performed quantitative and qualitative analyses on latently infected cells in nine
participants from the previously described AIDS Clinical Trials Group (ACTG) clinical
trial, A5340 (described in Chapter 3 of this thesis). The trial found that three infusions of
the broadly neutralizing antibody VRC01 was safe and well-tolerated, but only modestly
delayed the time to viral rebound compared to historical controls.
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Phenotypic and

genotypic analyses of pre-cART and rebound viruses determined that VRC01 was able
to restrict the clonality of rebound viruses, though pre-existing resistance to VRC01 led
to rapid viral rebound in the presence of high concentrations of plasma VRC01 in the
majority of participants. Upon collection of two consecutive plasma samples with viral
loads greater than 1,000 copies per milliliter, cART was reinitiated and all participants
achieved rapid suppression back to undetectable levels. Here, I determine the impact of
transient viremia with ATI by assessing the relationship between autologous viruses
derived from pre-cART plasma, rebound plasma, and PBMCs archived before and six
months after trial completion. I show that ATI does not substantially alter the size or
diversity of the peripheral latent reservoir.

Additionally, I also observed a high

prevalence of clonally-expanded replication-competent and genetically intact latent
viruses, which confounded attempts to successfully identify viruses that will reactivate in
vivo upon ATI.

Results
Patient population
Nine individuals participated in this component of the ACTG clinical trial A5340,
undergoing multiple blood draws and two leukapheresis and rectal biopsies. In this
study, I analyzed plasma and/or PBMC samples from four time points (Fig 4.1); Plasma
samples were obtained prior to ART initiation (available in 5 participants) and at the first
and second week of virus rebound after ATI. Plasma and PBMCs obtained by
leukapheresis at trial entry (prior to VRC01 administration or ATI) and six months after
plasma virus suppression <200 copies/ml with ART re-initiation were also studied.
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Further patient demographics information can be found in Table 4.1. Prior to the postATI leukapheresis, participants’ plasma virus was suppressed <200 copies/ml on cART
for a median of 34 weeks (range 23-44 weeks) and 35 weeks (range 23-43 weeks) prior
to the post-ATI rectal biopsy.

Quantitative measures of reservoir change
We performed several assays to quantitatively estimate within-person changes in the
size of the peripheral latent reservoir. Using PBMCs obtained during cART suppression
of viremia prior to ATI and six months after virus suppression on cART (Figure 4.1), we
selected CD4+ T cells and measured copies of total HIV-1 DNA and cell-associated
RNA by quantitative PCR (Figure 4.2). Total DNA levels ranged from 21.4 to 1791.2
copies/million CD4+ T cells pre-ATI and 25.4 to 1564.5 copies/million CD4+ T cells postATI. No significant change between the within-person pre- and post-ATI values was
observed, with a median (Q1, Q3) change of 0.08 (-0.13, 0.18) log10 copies/million cells,
P=0.313. Similarly, we did not observe any significant changes in cell-associated RNA
levels between pre- and post-ATI samples. RNA measures ranged from 6.1 to 10,834.7
copies/million cells with a median (Q1, Q3) change of -0.05 (-0.15, 0.2) log10
copies/million cells, P=0.734.

To determine the composition of replication-competent viruses from the latent reservoir,
we used the same PBMC samples pre- and post-ATI, and quantified the total number of
resting CD4+ T cells using a quantitative virus outgrowth assay (QVOA). We found that
the values for infectious units per million cells (IUPM) ranged from 0.033 to 16.248 IUPM
pre-trial and 0.023 to 8.35 IUPM post-trial. There was no evidence suggesting significant
within-person change, with a median (Q1, Q3) change of 0.3 (-0.16, 0.63) log10
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copies/million cells, P=0.652.

We also performed single copy assay (SCA) to detect

low-level viremia in plasma collected during suppressive ART before and after the trial
(Fig. 4.2). With a limit of detection of <0.5 copies/ml, 3 participants remained
undetectable before and after ATI, 3 participants were above detectable at both
timepoints, 1 participant went from just above detection (0.53 copies/ml) to undetectable,
while the remaining 2 went from undetectable to 2.14 and 2.19 copies/ml, respectively.

Several reports between latency measures have demonstrated a lack of correlation
between IUPM, HIV DNA, and SCA measures7,9,19. Here, we tested the association
between the three quantitative assessments at baseline, post-trial, and in the change
between timepoints. We identified a modest correlation between total DNA in CD4 T
cells and replication-competent virus (IUPM) by QVOA, with Spearman correlation
coefficients of 0.68 and (P=0.06) at baseline, 0.83 (P=0.01) at Step 3, and 0.79 (P=0.02)
for the change between baseline and post-ATI (Figure 4.3). No correlation between caRNA and other measures was detected. An association between undetectable plasma
virus by SCA and lower DNA and IUPM by QVOA was also seen. We also did not
observe any detectable virus in pre- or post-ATI samples in rectal tissues in the majority
of participants, however, we believe this was due to a technical issue that occurred
during tissue processing.

Phylogenetic analysis of reservoir change
To further evaluate whether brief ATI and transient viremia altered the genetic
composition of the viral reservoir, I used phylogenetic analyses to assess the viral
quasispecies in pre-ATI, rebound, and post-ATI archived samples.

Due to limited

sequence yield, Participant A14 was not included in this analyses. For the remaining
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eight participants, I sequenced full length HIV-1 Env using gp160 nested primers on
viruses replicating in p24+ culture wells of the pre- and post-trial QVOA assays. QVOA
wells were cultured with limiting dilutions of resting CD4+ T cells, therefore, in order to
eliminate cultures with multiple HIV-1 templates single genome sequencing methods
were used to identify culture wells with single templates and present the consensus
sequence of individual envs represented in individual culture wells (see methods). I then
compared QVOA-derived env sequences with SGS-derived gp160 env from plasma
samples sampled prior to cART initiation (pre-cART viruses), and plasma viruses
collected during the first and second rebound time points during ATI. These samples
were then analyzed collectively in a maximum likelihood (ML) phylogenetic tree, where
all participant sequences clustered independently (Fig. 4.4).

Clonal populations are prevalent within replication competent peripheral latent
reservoir
ML phylogenetic trees of each individual participant’s gp160 env sequences from the
three observed time points in this study show a range of diversity in pre-cART viruses
and low-diversity lineages during rebound with a maximum within-patient diversity
(range, 0.87%-6.1%) and tree structures indicative of chronic infection. Viral rebound
was polyclonal for 7 participants, showing multiple genetically distinct, low-diversity
rebound lineages supporting the hypothesis that rebound lineages arise from multiple
latently infected cells and replicates systemically within weeks of ATI7,14,15. When
assessing QVOA-derived sequences, I observed an interesting phenomenon in QVOA
sequence analyses, where multiple groups of identical env sequences are represented
in dependent culture wells. While whole genome analyses was not used in this study,
the sequences were generated through env specific primers with a clonal prediction
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score of 95, indicating a high likelihood that these identical env sequences also reflected
identical whole genomes20. While definitive proof of clonal expansion of latently infected
cells requires integration site analysis of identical viruses from different cells, modeling
and empiric studies support the hypothesis that multiple identical gp160 env sequences
are indicative of in vivo clonal expansion20–23.

Given that QVOA assays require 14 to 21 days of ex vivo stimulation and that the in vitro
error rate of HIV RT can cause an accumulation of errors during this period21,24–26, in my
analyses of clonal variants, I included viral sequences with up to two nucleotide
polymorphisms as a clonal lineage. All participants with more than two QVOA
sequences available per time point (A01, A02, A06, A08, A09 and A13), were found to
have clonal lineages through these methods. In four participants with more than 20
QVOA sequences available, clonal lineages comprised 68% of the total QVOA-derived
viruses assessed. A01 is a striking example of substantial clonal expansion, where the
replication-competent viruses from this participant comprised of 41 of 43 identical
viruses (95%) that were derived from pre-trial as well as post-trial QVOA samples.
Furthermore, we identify 6 of 11 (55%) identical QVOA viruses from participant A02
representing two clonal lineages, and multiple expanded lineages in participant A08,
representing 6 distinct lineages of 2 or more sequences, representing 48% (14 of 29) of
QVOA-derived viruses (Fig. 4.5).

Minimal enrichment of rebound sequences in the post-trial latent reservoir.
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I next assessed whether enrichment of rebound sequences could be observed in the
post-trial latent reservoir by comparing the genetic relatedness of rebound lineages to
pre-trial and post-trial QVOA lineages. I hypothesized that brief ATI would not lead to a
substantial accumulation of rebound viruses in the viral reservoir, indicated by the limited
number of identical post-trial QVOA and rebound sequences compared to pre-trial
QVOA sequences. In participants A01, A02, A05, A09 and A13 (Fig. 4.4, Fig. 4.5). I did
not find any evidence of post-trial QVOA sequences clustering with or near rebound
viruses. In contrast, I did identify two identical rebound and post-trial QVOA sequences,
as well as a minor lineage with both pre- and post-trial QVOAs. These data suggest
possible enrichment of the viral reservoir during viral rebound in this participant. In
addition, I identified 2 participants with small or low-diversity viral reservoirs before ATI,
which made phylogenetic interpretation of rebound and QVOA sequences more
challenging.

Participant A07, for example, had a very small replication-competent

reservoir, with only one pre-trial QVOA well available for assessment, and no available
wells post-trial, which prevented an accurate qualitative assessment of the reservoir at
pre- and post-trial time points. In addition, participant A06 contained a very narrow
within-patient diversity (maximum difference of 3 nucleotides or 0.12%), containing
rebound, pre- and post-trial QVOA sequences, which prevented us from accurately
distinguishing between discrete lineages. Together, I found that the frequencies of pretrial QVOA sequences (77%) and post-trial QVOA sequences (33%) aligned with this
rebound virus as suggesting the preexistence of this lineage before ATI, rather than
enrichment of this lineage from rebound viremia. Overall, in 5 of 6 evaluable participants,
limited relatedness of rebound and QVOA viruses suggests that transient viral rebound
does not substantially alters the composition of the latent reservoir.
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Limited relatedness of pre-ATI QVOA to rebound sequences.
I next asked whether pre-ATI QVOA sequences represent replication-competent viruses
that could reactivate upon treatment interruption. This analyses would be a useful tool in
predicting rebound viruses, which is of considerable interest to the HIV cure field.
Sequence analyses of pre-trial QVOA show a lack of correlation to rebounding virus
populations, and was especially notable in participants with large expanded clones of
pre-trial QVOA viruses, as indicated in participant A01. Interestingly, while participant
A01 contained 93% (13 of 14 sequences) identical pre-trial QVOA viruses, none of these
viruses from this replication competent expanded clone were sampled during ATI.
Instead, four genetically distinct, clonal lineages reactivated during ATI. This was also
observed in two other participants with clonal pre-trial QVOA lineages. In participant
A02, where 55% (5 of 9 sequences) from pre-trial QVOA made up two expanded clonal
lineages, though neither of these expanded clones reactivated in vivo. In participant A09,
30% (3 of 10 sequences) of pre-trial QVOA viruses made up a single clone, though the 7
distinct lineages that arose in vivo during rebound do not represent this in vitro expanded
clone. These results suggest that in most chronically-infected cART suppressed
participants, sampling of pre-trial QVOA viruses often leads to the identification of large,
clonally expanded populations, though these populations are not able to predict the viral
population that reactivates upon ATI.

Exceptions to this finding were found in

participants A07 and A02, where narrow diversity and limited reservoir size prevented
accurate distinction between rebound and QVOA lineages, and in participant A08, where
two pre-trial QVOA sequences were related to a minor rebound virus population (with 47 nucleotide differences).

Neutralization sensitivity to VRC01 and autologous plasma.
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Given that the majority of participants in this study contained clonally expanded,
replication-competent viruses that did not expand in vivo, I next asked whether one
potential mechanism preventing their expansion was related to the in vivo conditions
during rebound. High concentrations of VRC01 were circulating in the plasma at the time
of rebound in all participants with the exception of participant 07, who rebounded at 11
weeks with waning plasma concentrations.

Previous analyses of rebound virus

sensitivity to VRC01 determined that the prevalence of VRC01 resistance is high, and
contributes to the timing and clonality of the rebound virus population. Additionally, in
Chapter 2 of this thesis I describe a role for autologous antibodies during rebound in
restricting the replication of select neutralization-sensitive viral populations at longitudinal
rebound timepoints. Therefore, I hypothesized that large, clonally expanded viruses
derived by QVOA were not represented in the rebounding virus population upon ATI and
VRC01 infusion due to increased VRC01 sensitivity and circulating autologous antibody
responses generated at the time of viral rebound.

To test this, I generated HIV-1 Env pseudpotype viruses from the cloned consensus
sequence of distinct QVOA, rebound, and pre-cART lineages from participants A01,
A02, A06, and A09 (as shown in Figures 4.4 and 4.5). These pseudotypes were
assessed for neutralization sensitivity (by IC80) to VRC01. Interestingly, I found no
differences in VRC01 neutralization curves across QVOA, rebound, and pre-ART envs in
either participant. To determine whether autologous antibodies had a differential role in
restricting viral replication during ATI, the same Env pseudoviruses were tested for
sensitivity to autologous plasma collected at first detectable viral rebound.

This

timepoint contained both the exogenously administered VRC01 as well as circulating
polyclonal autologous neutralizing Abs (Figure 4.6). Although the limited number of
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available Env pseudotypes for each participant prevented robust statistical comparisons,
across all participants, I observed a trend toward greater sensitivity to autologous
plasma in QVOA viruses compared to rebound viruses for all participants, suggesting
autologous antibodies generated at the time of viral rebound may inhibit replicationcompetent, clonally expanded viruses from rebounding during ATI and VRC01 infusion.

Phylogenetic analysis of intact gp160 env from resting CD4+ T cell proviral DNA.
While sequencing of QVOA viruses allows for an assessment of replication-competent
viruses within the viral reservoir, sampling depth is extremely limited and provides only a
minimal estimate of viruses that could potentially reactivate under ATI conditions. To
address this, I performed SGS on proviral DNA from resting CD4+ T cells collected
before and up to six months after ATI. While the majority of proviruses in the reservoir
have been shown to be defective variants23,27–29, I restricted my analyses to sequences
without hypermutations, multiple templates, or incomplete gp160 open reading frames.
Through these methods, I generated 546 intact sequences (median 70 per participant).
By including these sequences into the ML phylogenetic trees containing pre-cART,
rebound, and pre- and post-trial QVOA sequences, I identified additional evidence of
clonal expansion within the viral reservoir (Fig. 4.7 and Fig. 4.8). Similar to QVOA
sequence analyses, I found that all 8 participants harbored multiple populations of
identical proviral DNA sequences, with clonal populations comprising a range of 5% to
78% of the total sequenced proviral DNA population. Interestingly, I also found a low
degree of overlap between proviral DNA and QVOA sequences. Participants A02 and
A13, for example, contained expanded clones that comprised 61% and 78% of the
proviral DNA population, respectively (Fig. 4.7, Fig. 4.8).

, though these expanded

populations did not match the clonal populations observed in pre- or post-trial QVOA

113

analyses. This low level of overlap between proviral and QVOA sequences was
observed across all participants. Participant A01 was another striking example, where
the 95% clonal population observed by QVOA represented only 2% of the proviral DNA
sequences samples (Fig. 4.7). In contrast, participant A09 did contain matched proviral
DNA and QVOA sequences (Fig. 4.8).

While proviral DNA sequencing expanded the pool of latent viruses in each participant,
similar to QVOA analyses, the vast majority of participants (A01, A02, A05, A06, A08
and A09) did not contain overlapping proviral DNA and rebound sequences. In addition,
expanded clonal populations identified in pre-trial proviral DNA (A02 and A13) also did
not predict rebounding viruses. The only exception to this finding was participant A07,
and supports the hypothesis that this participant contains a limited reservoir compared to
all participants, with a small pool of replication-competent identical to near identical
latent viruses. Together, these data support the findings of my QVOA analyses that
transient viremia during brief ATI does not substantially change the composition of the
latent reservoir.

Statistical comparisons of virus populations.
We also sought to determine the relatedness of these distinct viral compartments
through genealogical sorting indices (GSI) (Table 4.2)30. The GSI tests the phylogenetic
similarities of two sequence groups, with the null hypothesis that the virus populations
were the same; GSI values range from 0 (complete interspersion) to 1 (complete
monophyly), with statistical significance indicating greater than random segregation
between groups. Through these analyses, we found that the majority of participants had
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highly interspersed latent pre- and post-ATI virus populations. Participant A08 was the
only participant in this study with a statistically and significantly high GSI value,
suggesting that the composition of the replication-competent viruses changes over time.
For the remainder of the participants, these highly interspersed pre- and post-ATI
sequence sets support the concept that ATI does not substantially alter the sampled
reservoir.

To determine statistical relatedness of pre- and post-ATI sequences of QVOA and
proviral DNA sequences, pre- and post-ATI sequences were grouped together and
QVOA and proviral DNA viruses were compared. Interestingly, through these analyses
we found that in 5 of 6 evaluable participants (those with >2 QVOA sequences per time
point), there were significant (P < 0.05) differences between QVOA and proviral DNA
viruses sampled from the same leukapheresis-derived resting CD4+ T cells. When
comparing QVOA and proviral DNA viruses with rebound viruses, we found that latent
viral sequences differed significantly (P < 0.001) from rebound.

We also used a non-tree–based method to examine sequence differences among the
same virus populations. Here, we tested the null hypothesis that the distributions of
Levenshtein edit distance were the same when comparing virus populations with
themselves and with other virus populations (Fig. 4.8). Similar to the GSI results, we
found highly similar LDs among pre- and post-ATI QVOA and proviral DNA sequences.
Then, we grouped the pre- and post-ATI sequences together and compared proviral
DNA with QVOA sequences (Fig. 4.8, right box for each participant). When we grouped
pre- and post-ATI sequences together and compared proviral DNA with QVOA
sequences, we found statistical significance in the same participants as with the GSI
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method, with the exception of participant A09, in whom an extremely high intrapopulation
genetic diversity pre-vented distinction between QVOA and proviral DNA sequences.
Finally, comparisons of rebound sequences with QVOA and proviral DNA showed highly
significant differences in all participants except those with limited or narrow QVOA
sequence populations (A06 and A07). Thus, both statistical methods supported
phylogenetic analysis results suggesting that ATI did not substantially change the
composition of the reservoir and that the QVOA, proviral DNA, and rebound virus
populations all differed substantially from each other.
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Tables

Table 4.1 Baseline, clinical, and study characteristics from A5340 Step 3. This work
was reprinted with permission from the Journal of Clinical Investigation.

Table 4.2 Genealogical Sorting Indices. This work was reprinted with permission from
the Journal of Clinical Investigation.
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Figures

Figure 4.1 A5340 Step 3 Study Schema. The A5340 clinical trial schema is shown at
the top, with the type and timing of clinical specimens obtained for the present study
shown in the center, and the assays performed shown at the bottom. This work was
reprinted with permission from the Journal of Clinical Investigation.

Figure 4.2 Single copy assay. Single copy assay was performed to detect low-level
viremia in plasma collected during suppressive ART before and after the trial. With a
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limit of detection of <0.5 copies/ml, 3 participants remained undetectable before and
after ATI, 3 participants were above detectable at both timepoints, 1 participant went
from just above detection (0.53 c/ml) to undetectable, while the remaining 2 went from
undetectable to 2.14 and 2.19 copies/ml, respectively. This work was reprinted with
permission from the Journal of Clinical Investigation.

Figure 4.3 Quantitative measures of reservoir change. Pre-ATI and post-ATI values
(Obtained at study entry and more than 6 months after viral suppression following cART
reinitiation, respectively) of total HIV-1 DNA in CD4+ T cells. A. Cell-associated HIV-1
RNA (caRNA) in CD4+ T cells, B. and the frequency of resting CD4+ T cells bearing
replication-competent virus (IUPM) C. are shown for each participant. Total DNA is not
shown for participant A06 because the values were below detectable levels at both time
points. P values shown in A-C inficate the significance of the within-participant changes
and were determined by Wilcoxon signed-rank test. This work was reprinted with
permission from the Journal of Clinical Investigation.
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Figure 4.4 ML phylogenetic trees of SGS-derived gp160 env sequences from preART plasma, rebound plasma, and replication-competent latent viruses
(Participants A01, A02, A05, A06, A07). Env sequences from pre-ART plasma are
shown as black circles, sequences from rebound plasma from the first and second
weeks of detectable viremia after ATI are shown as red and orange triangles,
respectively, and sequences from virus supernatant from individual pre- and post-ATI
p24+ QVOA culture supernatants are shown as solid blue or open blue squares. Genetic
distance is shown by the scale bar, indicating 5 nucleotides (or ~0.2% difference).
Bootstrap values above 70 are indicated by asterisks. Envs tested for neutralization
sensitivity in participants A01, A02, and A06 are indicated with an inverted v (^).
Populations of identical QVOA sequences are seen in participants A01, A02, and A06,
including a single dominant clone in participant A01 representing 95% of all QVOA
sequences. Rebound sequences are generally distinct from QVOA sequences, except in
participant A06, in which limited genetic diversity challenged distinction and in A07, in
which the single QVOA sequence aligned with a rebound lineage. This work was
reprinted with permission from the Journal of Clinical Investigation.
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Figure 4.5 ML phylogenetic trees of SGS-derived gp160 env sequences from preART plasma, rebound plasma, and replication-competent latent viruses (A08, A09,
A13). Participants A08, A09, and A13 shown above. Genetic distance is shown by the
scale bar, indicating 5 nucleotides (or ~0.2% difference) for participants A08 and A13,
and 20 nucleotides (~0.8% difference) for participant A09. Envs tested for neutralization
sensitivity in participants A09 are indicated with an inverted v (^). Populations of identical
QVOA sequences are seen in participants A08, A09, and A13. Viral rebound sequences
are distinct from QVOA sequences in participants A09 and A13; in participant A08, some
pre- and post-ATI QVOA sequences are identical or nearly identical to rebound lineages.
This work was reprinted with permission from the Journal of Clinical Investigation.
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Figure 4.6 Neutralization sensitivity to VRC01 and autologous plasma at the time
of viral rebound. Representative Envs from 4 participants were cloned and tested as
pseudoviruses in infectivity assays for sensitivity to VRC01 and autologous plasma.
Representative infectivity curves for the rebound and QVOA Envs for participant A01 are
shown against VRC01 (A) and autologous plasma (B). All assays were performed in
triplicate, and the mean infectivity ± SEM for each dilution is shown. The mean IC80 for
virus inhibition against VRC01 (C) and autologous plasma (D) is shown for 4
participants. Pre-ATI viruses are shown in black, QVOA viruses in blue, and rebound
viruses in red. This work was reprinted with permission from the Journal of Clinical
Investigation.
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Figure 4.7 ML phylogenetic trees of SGS-derived gp160 env sequences from preART plasma, rebound plasma, replication-competent latent viruses, and
genetically intact proviral DNA (Participants A01, A02, and A05–A07). Env
sequences from pre-ART plasma are shown as black circles, sequences from rebound
plasma from the first and second weeks of detectable viremia after ATI are shown as red
and orange triangles, respectively, sequences from virus supernatant from pre- and
post-ATI individual p24+ QVOA culture well supernatants are shown as solid blue or
open blue squares, and sequences from pre- and post-ATI proviral DNA (pDNA) are
shown as solid purple or open purple diamonds. For clearer visualization, identical
sequences are aligned horizontally in rows of 5. Genetic distance is shown by the scale
bar, indicating 5 nucleotides (or ~0.2% difference) in all trees. Bootstrap values above
70 are indicated by asterisks. Populations of identical proviral DNA sequences are seen
in all participants, including a large clonal population in participant A02 comprising 61%
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of total proviral DNA sequences. In general, the larger clonal populations of proviral DNA
sequences show limited or no overlap with the larger QVOA clones. This work was
reprinted with permission from the Journal of Clinical Investigation.

Figure 4.8 ML phylogenetic trees of SGS-derived gp160 env sequences from preART plasma, rebound plasma, replication-competent latent viruses, and
genetically intact proviral DNA (Participants A08, A09 and A13). Populations of
identical proviral DNA sequences were found all participants, including a single clone
comprising 78% of the proviral DNA sequences for participant A13, which was not
sampled in the QVOA sequences. This work was reprinted with permission from the
Journal of Clinical Investigation.
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Figure 4.9 Comparisons of pairwise Levenshtein Distances between virus
populations. For each participant, pairwise Levenshtein edit distance between
nucleotide sequences sets are shown. Rebound sequences are labeled R, QVOA
sequences are labeled Q, Proviral DNA sequences are labeled C, and pre-ART
sequences are labeled PC. In the box on the left, comparisons between viruses from
each timepoint are shown (i.e., Q1 is pre-ATI QVOA sequences and Q2 is post-ATI
QVOA sequences). In the box on the left, sequences from the pre- and post-ATI
samples are combined. Statistical significance by PERMANOVA after Bonferroni
correction for multiple comparisons is indicated by the heat map. This work was
reprinted with permission from the Journal of Clinical Investigation.
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Discussion
ATIs are a valuable tool commonly used in HIV curative trials to assess the efficacy of
novel curative therapies in the absence of cART1,17,31,32. While closely monitored ATIs
prevent long periods of viral replication without intervention, there are several safety
concerns with altering the size and composition of the viral reservoir during rebound.
Using a unique collection of pre-trial and post-trial samples available from clinical trial
A5340 (Fig. 4.1), we were able to assess the effect of brief ATI with transient rebound
viremia in HIV-infected individuals. Participants in this study reinitiated their original
cART regimen and remained virally-suppressed for at least 6 months before post-trial
samples were collected in order to ensure sampling of latently infected cells. In this
study, we found no statistical increase in the size of the latent reservoir through
measurements of viral transcripts by total HIV-1 DNA, cell-associated RNA, or IUPM.
Collectively, these data suggest that the latent reservoir does not expand during ATI.
While HIV DNA and RNA measures have not previously been shown to correlate with
the number of replication-competent viruses assessed in QVOA assays due to the high
number of defective viruses present in the viral reservoir, our measurements of HIV-1
DNA and RNA correlate with IUPM, suggesting our sampling methods are measuring a
biologically relevant population of viruses.

To determine whether ATI can change the composition of the viral reservoir, we next
performed QVOA assays on resting CD4+ T cells collected from pre-trial and post-trial
time points and assessed the diversity of latent replication-competent viruses that
expanded in vitro. Through SGS and phylogenetic analyses, I found that QVOA viruses
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from pre- and post-trial time points had minimal nucleotide changes and were distinct
from the rebounding virus population in the majority of participants. I also observed two
exceptions to this finding in participant A07 and A02, where the reservoir size was small
(A07) or narrow (A02), thus preventing distinction between rebound viruses and QVOA
viruses.

While QVOA assays are a useful measure of replication-competent viruses from the
latent reservoir, these methods can be highly resource intensive18,33, and provide only a
limited snapshot of the viral reservoir. Therefore, we sought to increase the number of
HIV sequences in our analysis by sequencing proviral DNA from resting CD4+ T cells
from pre- and post-trial leukapheresis time points. Proviral DNA sequencing substantially
increase the number of HIV env sequences from latently infected cells. Similar to QVOA
sequence analyses, I found that genetically intact proviral DNA from pre- or post-trial
time points did not align with rebounding viruses in most participants.

Like QVOA

viruses, I also found that while large, clonally expanded lineages were prevalent in
proviral DNA (Fig 4.6-4.7), these sequences are still not predictive of viral rebound. An
additional finding in our sequence analyses was that pre- and post-trial proviral DNA
sequences remained stable over time. This is in contrast to a recently published study
that have suggests latently infected, clonally expanded cells wax and wane over time33.
This was supported by non-tree based statistical testing, where no statistical differences
can be observed between pre- or post-trial samples, even in participants with small or
narrow viral reservoirs. Collectively, these data suggest that brief ATIs followed by rapid
viral suppression with cART do not substantially increase the size or diversity of the
latent reservoir. This finding is significant, in that future curative trials will need to
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determine drug efficacy in individuals who initiated cART early in infection, where the
reservoir is potentially smaller and less diverse34–36.

The observation of large identical lineages in QVOA and proviral DNA sequences from
pre- and post-trial time points is also notable, as it supports the hypothesis that clonal
expansion of latently infected cells is prevalent and may also contribute to the size and
diversity of the viral reservoir over time23,24,27–29,37. While we did not perform integration
site analysis in this study, the primers used in our analyses are 95% likely to predict
identical whole-genome sequencing, while mathematical modeling supports the finding
that identical sequences are highly likely to predict clonally expanded cell
populations20,22,23,38.

In the A5340 clinical trial, increased VRC01 sensitivity was associated with delayed
rebound kinetics and clonal restriction of viruses that arose from the latent reservoir. In
this study, in vitro neutralization assays with VRC01 did not identify increased sensitivity
to VRC01 in QVOA viruses compared to autologous pre-cART and rebound viruses,
suggesting VRC01 is not implementing a “sieve effect” on the latent viral pool. Previous
studies have suggested autologous plasma may exert selective pressure on rebounding
variants during ATI, and are described in greater detail in Chapter 2 of this thesis. Using
the same Env pseudotypes and heat-inactivated autologous plasma from first detectable
rebound, I tested the hypothesis that autologous antibodies also exert selection pressure
on rebounding viruses during ATI and VRC01 infusion.

While the number of Env

pseudotypes tested was limited, I found that QVOA viruses had increased sensitivity to
autologous antibodies, suggesting that autologous antibodies may drive the selection of
rebound.
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In summary, these results provide reassurance that brief, closely monitored ATIs with
rapid resuppression of cART do not substantially alter the size or composition of the
latent reservoir. These findings are especially important for future HIV cure trials that will
need to assess the efficacy of each therapeutic strategy under the context of ATI in
chronically infected individuals39.

Materials and Methods
Study participants
The ACTG clinical trial A5340 (ClinicalTrials.gov NCT02463227) tested the safety and
ability of the bNAb VRC01 to maintain viral suppression during ATI. The study design,
approvals, and results were published previously (17). All A5340 trial participants who
opted to undergo leukapheresis were included in this study (n = 9). Participant A14 was
excluded from the qualitative analysis because of an insufficient number of rebound
plasma env sequences and a limited number of p24+ QVOA wells.

Quantification of total HIV-1 DNA and cell-associated RNA
CD4+ T cells were isolated from PBMCs using an EasySep Human CD4+ T cell
Enrichment Kit (STEMCELL Technologies). Cellular RNA and DNA from isolated CD4+
T cells were purified using the AllPrep DNA/RNA Kit (QIAGEN) as specified by the
manufacturer, quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher
Scientific), and normalized to cell equivalents by qPCR using human genomic TERT for
DNA and RPLP0 expression for RNA (Life Technologies, Thermo Fisher Scientific).
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Total cellular HIV-1 DNA and RNA were quantified with a qPCR TaqMan assay using
the LTR-specific primers F522-43 (5′-GCCTCA-ATAAAGCTTGCCTTGA-3′; HXB2522–
543) and R626- 43 (5′ GGGCGCCACTGCTAGAGA-3′; 626–643), coupled with a
FAMBQ probe (5′-CCAGAGTCACACAACAGACGGGCACA-3′) using the QuantStudio 6
Flex Real-Time PCR System (Applied Biosystems). The cell-associated HIV-1 DNA copy
number was determined using a reaction volume of 20 μl with 10 μl of 2X TaqMan
Universal Master Mix II with UNG (Life Technologies, Thermo Fisher Scientific), 4 pmol
of each primer, 4 pmol probe, and 5 μl DNA. Cycling conditions were 50ºC for 2 minutes,
95ºC for 10 minutes, and then 60 cycles of 95ºC for 15 seconds and 59ºC for 1 minute.
The cell-associated HIV-1 RNA copy number was determined in a reaction volume of 20
μl with 10 μl of a 2Å~ TaqMan RNA-to-Ct 1-Step Kit (Life Technologies, Thermo Fisher
Scientific), 4 pmol of each primer, 4 pmol probe, 0.5 μl reverse transcriptase, and 5 μl
RNA. Cycling conditions were 48ºC for 20 minutes, 95ºC for 10 minutes, and then 60
cycles of 95ºC for 15 seconds and 59ºC for 1 minute. For HIV-1 DNA measurements,
external quantitation standards were prepared from the ACH-2 cell line in a background
of HIV-1–negative human cellular DNA and calibrated to the Virology Quality Assurance
(VQA) (NIH DAIDS) cellular DNA quantitation standards. For HIV RNA measurements,
external quantitation standards were prepared from full-length NL4-3 RNA, followed by
copy number determination using the Abbott RealTime assay (Abbott Diagnostics) and
calibrated to VQA HIV-1 RNA standards. Patient specimens were assayed with up to
800 ng total cellular RNA or DNA in replicate reaction wells and the copy number
determined by extrapolation against a 7-point standard curve (1–10,000 cps) performed
in triplicate. DNA values for 1 participant measured under the limit of detection with
fewer than 21.4 copies/million CD4+ T cells were censored at 21.4 copies/million CD4+
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T cells throughout the analyses. DNA values for A06 are not shown because of assay
failure secondary to a primer mismatch.

Single-copy assay
Residual plasma HIV viremia was measured using the validated ultrasensitive integrase
single-copy assay (iSCA)40. Plasma from the participants was spiked with an internal
RCAS virion26 standard, and qPCR reactions were performed with a Roche LightCycler
480 system using primers and probes specific to a conserved area of the HIV integrase
gene.

QVOA
Resting CD4+ T cells (30.5 million) from leukapheresis derived PBMCs from individual
HIV-1–infected participants and purified by 2-step magnetic bead depletion (CD4+ T cell
Isolation Kit and CD69 Microbead Kit II, both from Miltenyi Biotec). Resting CD4+ T cells
were then serially diluted 5-fold, briefly cocultured with a 10-fold excess of γ-irradiated
allogeneic PBMCs from uninfected donors, and stimulated with RPMI containing
phytohemagglutinin (PHA) (Remel), 10% FBS 100 U/ml IL-2 (Novartis), and 1% T cell
growth factor (produced by the Siliciano laboratory as previously described, ref. 44.
Media were removed 1 day after mitogen stimulation, and target MOLT-4/CCR5 cells
were added to fresh media to propagate replication-competent HIV-1. The ratios of
target cells were 1x107 to 1x106 patient resting CD4+ T cells to 2.5x106 target cells. Five
days after stimulation, culture media were replaced, and cells in each well were split.
Supernatants from each well were then assessed for p24 protein by qPCR and ELISA to
determine the presence of replication competent virus on days 14 and 21 (Alliance HIV-1
p24 antigen ELISA Kit, PerkinElmer). The frequency of latently infected cells among the
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input resting CD4+ T cells was calculated by a ML method, as described previously, and
expressed as IUPM, and 95% CIs for individual IUPM determinations were ±0.7 log
IUPM, or 5-fold41. Using the ML method, samples without replication-competent virus
were assessed in analyses as the limit of detection of the assay, based on cell input.
Supernatant from wells containing replication-competent virus was then collected and
processed by SGS methods.

SGS of replication-competent virus from QVOA wells
Viral RNA from p24+ wells collected in MOLT-4/CCR5 QVOA assays was extracted
using the QIAmp viral RNA Mini Kit (QIAGEN) according to the manufacturer’s
instructions. HIV cDNA was generated by incubating 30 μl template RNA with 3 μl 10
mM

dNTPs

and

0.75

μl

of

20

μM

antisense

primer

R3B3R

(5′-

ACTACTTGAAGCACTCAAGGCAAGCTTTATTG-3′) for 5 minutes at 65ÅãC to denature
the RNA, followed by reverse transcription using SuperScript III Reverse Transcriptase
(Life Technologies, Thermo Fisher Scientific) according to the manufacturer’s
instructions. Amplification of gp160 env genes was performed by nested PCR using
Platinum Taq High Fidelity Polymerase (Life Technologies, Thermo Fisher Scientific) as
previously described31. In order to ensure that a majority of sequences would be
generated from a single template, cDNA was diluted to yield less than 30% PCR-positive
products on a precast 1% agarose gel (Thermo Fischer Scientific). Three to eight
amplicons per QVOA sample were sequenced on an Illumina MiSeq platform; only wells
with identical consensus sequences (85% identity at each nucleotide position) were
used for analysis. Divergent sequences derived from the same QVOA well indicate
evidence of multiple viruses, and were excluded from analysis. Sequences that
contained stop codons, large deletions, or mixed bases were also excluded from further
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analysis. Sequences were codon aligned using MUSCLE in the Geneious suite (version
8.1.7), manually refined, and gap-stripped. Phylogenetic trees were inferred using
ML/rapid bootstrapping in RAxML, version 8, run on the Cyberinfrastructure for
Phylogenetic

Research

(CIPRES)

Science

Gateway

(http://www.phylo.org/).

Evolutionary models were chosen for each participant data set using jModelTest (version
2.1.4), and model parameters were estimated concurrently with the phylogram topology.
Trees were mid-point rooted and visualized using MEGA, version 621, and bootstraps
greater than 70 are shown in the figures. All sequences were deposited in GenBank
(accession numbers MH263749 and MH264427).

SGS of proviral DNA from pre- and post-trial resting CD4+ T cells
Viral DNA was extracted from multiples of 4 million resting CD4+ T cells from pre- and
post-trial time points according to the manufacturer’s instructions (QIAamp DNA Mini
and Blood Mini Kit, QIAGEN). Amplification of gp160 env genes was performed as
described above. Amplicons were run on precast 1% agarose gels (Thermo Fisher
Scientific), and bands of appropriate size were directly sequenced on the Illumina MiSeq
platform. Sequences were inspected for evidence of priming from multiple templates,
stop codons, large deletions, or introduction of PCR error in early cycles; a threshold of
85% identity at each nucleotide position was used. Only sequences with full gp160 env
ORFs and no evidence of multiple templates were used in analysis. Sequences were
codon aligned using MUSCLE in the Geneious suite (version 8.1.7), manually refined,
and gap-stripped.

Env cloning, pseudovirus titering, and neutralization assays
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Select env sequences from pre-ART, rebound, and pre-trial QVOA samples were
molecularly cloned for the production of pseudovirus and phenotypic analyses as
described previously1. Amplicons identified by gel electrophoresis were gel purified using
the QIAquick Gel Purification Kit (QIAGEN), ligated into the pcDNA 3.1 Zeo(+)
Expression Vector (Invitrogen, Thermo Fisher Scientific), and transformed into NEB 5alpha Competent E. coli (New England BioLabs). Transformed bacteria (100 μl) were
plated onto Luria broth (LB) agar plates supplemented with 50 μg/ml ampicillin and
cultured at 37ÅãC for 24 hours. Single colonies were selected and grown overnight in
liquid LB broth at 37ÅãC with shaking at 250 rpm, followed by plasmid isolation. Finally,
each molecular clone was sequence confirmed against the reference env amplicon
using the Illumina MiSeq platform. Pseudovirus was prepared as described previously1.
Culture supernatants were harvested 48 hours after transfection, and pseudoviruses
were titrated on TZM-bl reporter cells. Virus neutralization by VRC01 or heat-inactivated
autologous plasma collected at the first detectable rebound was assessed on TZM-bl
cells as described previously1. All assays were performed in triplicate in each of at least
2 independent experiments. To calculate the concentration of VRC01 or dilution of
autologous plasma that neutralized 50% (IC50) and 80% (IC80) of the viral infection, the
Ab dose-response curves were fitted with a 4-parameter logistic regression equation
using GraphPad Prism 5.0 (GraphPad Software). The bNAb VRC01 was obtained from
the NIH AIDS Reagent program.

Statistics
Given the small sample size (n = 9), nonparametric tests were used for all comparisons.
The test for within-person changes from pre-ATI to post-ATI in measures of the latent
reservoir was performed using a Wilcoxon signed-rank test. Spearman’s correlation
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testing was used to test the association between measures. Analyses were conducted in
SAS, version 9.4 (SAS Institute). A P value of less than 0.05 was considered statistically
significant.

GSI
To assess similarities between sampled virus populations, within-person ML phylogenies
of combinations of QVOA sequences, proviral DNA sequences, and viral rebound
sequences were inferred using PhyML version 3.0, and GSI values were calculated
using the genealogical Sorting R package (http://molecularevolution.org/software/
phylogenetics/gsi/download)30. Statistical significance was assessed by randomly
permuting character states across the tips of the tree 10,000 times. Nonsignificant
values indicate the absence of compartmentalization (P values were corrected for
multiple tests).

Pairwise PERMANOVA of LDs
For each participant, we calculated the pairwise PERMANOVA of the LD between
nucleotide sequence sets that were aligned and gap-stripped. We then performed
pairwise comparisons between all sample populations using PERMANOVA to test the
null hypothesis that the centroids and spreads of the 2 populations were the same. P
values were adjusted by Bonferroni’s correction for the number of tests [n x (n – 1)/2].

Study approval
The ACTG clinical trial A5340 was conducted under approval of the IRBs of the
University of Pennsylvania and the University of Alabama at Birmingham. Written
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informed consent was obtained from all participants. The study protocols and results
were published previously1.
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CHAPTER 5
Discussion
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Overview
In HIV-infected individuals, daily cART can effectively and durably suppress plasma viral
loads to undetectable levels; however, cART is unsuccessful as a curative strategy for
HIV due to the persistence of the latent reservoir despite cART. In most individuals,
when cART is discontinued, latently infected cells residing in the viral reservoir can
reactivate and establish systemic rebound viremia within 4 weeks1–6. These long-lived,
persistently infected cells are the target of novel curative strategies for HIV. Without
known nonviral biomarkers to accurately assess how these strategies affect the latent
reservoir, ATIs are currently the preferred method to test efficacy of interventions by
assessing the duration of viral suppression in the absence of cART. Clinical trials
utilizing ATIs with novel curative strategies against HIV present a unique opportunity to
assess the virologic and immunologic consequences of rebound viremia and determine
mechanisms of treatment failure.

Early studies utilizing ATIs for this purpose have

primarily focused on the viral kinetics and initial diversity of the rebound viral
quasispecies.

The effects of ATI on both the evolution of HIV and host immune

responses, however, are poorly understood. In this thesis, I use longitudinal SGS,
molecular cloning, and neutralization assays on archived plasma and PBMC samples
from two previously conducted clinical trials to better understand the virologic and
immunologic events occurring during brief and extended periods of ATI. These data
address the initial clonality of rebounding HIV-1 variants (Chapter 2), the effect of hostderived and passively infused neutralizing antibodies on viral evolution (Chapters 2, 3
and 4), as well as changes in the size and composition of the latent reservoir during brief
periods of transient viremia (Chapter 4). These results provide important quantitative and
qualitative information regarding the effect of rebound on viral and host immune
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dynamics and will inform our understanding of mechanisms of both treatment failure and
success for curative strategies for HIV.

Clonality of the viral rebound quasispecies
One previously published ATI study has shown that the expansive initial diversity of
recrudescent viremia is consistent with viral replication arising from multiple latently
infected cells4.

The in vivo processes governing viral evolution of the rebound

quasispecies, however, are unknown. In this thesis, I use single genome amplification
and direct amplicon sequencing (SGS) of HIV-1 env to determine the precise genotypic
diversity of individual plasma-derived and proviral HIV-1 variants over multiple time
points during extended ATI. These methods provide a snapshot of the peripheral
diversity and clonality of the rebounding viral quasispecies in chronically-infected
participants over time and inform our understanding of viral evolution under ATI
conditions. I hypothesized that the plasma virus population would rapidly accumulate
diversity through the continuous stochastic activation of genetically distinct latent viruses
coupled with the ongoing evolution of early rebound viruses. Consistent with my
hypothesis, as described in Chapter 2 of this thesis, I observed that at baseline, the viral
quasispecies had a substantial increase in intrapatient diversity at first detectable
rebound (maximum diversity 6.07%) compared to early time points during acute viremia
in the same patients (maximum diversity 0.47%) 3–5,7.

With access to archived plasma samples from subsequent ATI time points, I was also
able to investigate patterns of viral evolution during rebound. Rather than the continuous
and random evolution of early rebound variants, which would be consistent with a
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Poisson-Fitter model of viral evolution in the absence of selective pressures, I instead
observed that select viral lineages were no longer sampled at later time points, indicating
that a population bottleneck had occurred in the participants studied. In participant S25,
for example, I observed complete replacement of the viral quasispecies at the time of
first detectable rebound after only four additional weeks of treatment interruption. This
rapid replacement of early viral lineages suggests that anti-HIV host immune responses
are rapidly emerging during ATI and preventing select variants from replicating.

Importantly, further visual inspection of gp160 env sequences within participants showed
that clonal expansion of replication-competent viruses was common. In Chapters 2 and
3, I found that multiple clonal lineages arose from latency to establish rebound viremia.
This finding was also observed in Chapter 4 of this thesis, where large, expanded clonal
lineages of full length gp160 env were identified in proviral DNA from resting CD4+ T
cells. This is in contrast to previously published data suggesting that defective viruses,
characterized by large internal deletions or APOBEC3-mediated mutations, are often
found in expanded T cell clones, while replication-competent viruses exist in quiescent,
non-expanding cells7,8. Using nested PCR and SGS, I was able to selectively amplify
and sequence viruses containing full length gp160, and identified multiple clonal
replication-competent viruses within both the plasma virus population and the PBMCderived latent reservoir. My data, in agreement with previously published reports,
supports the hypothesis that clonally expanded cells contribute to the persistence of the
replication-competent reservoir1,7. These findings complicate efforts to eradicate HIV, as
current therapies targeting the reservoir function under the assumption that clonal
expansion does not substantially contribute to the replication-competent viral
quasispecies9.

143

The clinical trials used for describing the diversity and clonality of the rebound viral
quasispecies have several important limitations. First, the study sizes were limited to 11
(Chapter 2), 13 (Chapter 3), and 9 (Chapter 4) male participants. Future work should
use larger, more diverse cohorts with extensive sampling to ensure that these studies
have the statistical power to be more informative. Second, the rebound period described
in Chapters 3 and 4 was brief (only 2 weeks), preventing extensive analyses of latently
infected cells that could have emerged at later ATI time points. Third, all participants
studied initiated cART during chronic infection. Viral diversity during chronic infection is
significantly greater than what is observed during acute infection10–12. Therefore, our
findings regarding rebound clonality cannot be extrapolated to patients who initiated
cART during acute infection. Fourth, all viruses analyzed in this thesis were from the
peripheral blood; as multiple reports have described that the majority of HIV target cells
reside in lymphoid tissues that may be sanctuary sites for HIV replication, this may be
considered a limitation of our studies4,13. Additionally, recent work in a mouse model for
HIV-1 has shown that clonally expanded HIV-1 infected cells are distributed in multiple
organs, and frequently integrate into genes associated with lymphocyte activation,
proliferation, and chromatin regulation14. Future work should consider sampling diverse
anatomical sites, such as lymphoid tissues, and should also focus on identifying the
molecular drivers of clonal expansion to inform future interventions that will need to
target cell-intrinsic mechanisms to prevent reservoir persistence.
Rebound kinetics to evaluate effect of treatment
Viral kinetic modeling has been used to better understand the within-host dynamics of
HIV-1 viral replication and the effects of antiretroviral therapy15–17. Modeling of viral
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kinetics during rebound for these same purposes has not been previously described.
The A5340 clinical trial provided the first opportunity to understand rebound viral kinetics
in the context of high circulating plasma concentrations of VRC01. In Chapter 3 of this
thesis, I hypothesized that VRC01 infusions would result in a significant delay in the time
to viral rebound compared to historical controls by exerting selective pressure on
VRC01-sensitive latent reservoir viruses. Consistent with my hypothesis, 38% of VRC01
trial participants remained suppressed at week 4 of ATI compared to 13% of patients in
historical controls3,4. In Participants A02 and A07, detectable viremia emerged at 8 and
11 weeks respectively, and corresponded with IC50 neutralization titers <1 µg/ml. This
was in contrast to the remaining 11 participants who experienced rapid viral rebound and
had an identifiable proportion of viruses from the plasma virus population that had
moderate resistance to VRC01 (range, 1.9 to >50.0 µg/ml). These findings suggest that
viral rebound kinetics can be used to evaluate the efficacy of bNAb infusions in
participants who have pre-existing bNAb resistant and sensitive viruses.

SGS and neutralization assays elucidate mechanisms of failure.
In addition to viral kinetics, the phenotype of circulating plasma viruses can also be used
to elucidate mechanisms of treatment failure. In Chapter 3 of this thesis, I explored
whether SGS could elucidate mechanisms of VRC01 failure by identifying genetic
patterns in the rebound viral quasispecies. It is important to note that regardless of the
time to viral rebound, resistance to VRC01 increased almost universally in rebound
plasma viruses (mean increase by a factor of 3.44, P=0.006 by a two-sided randomeffects model) compared to pre-cART plasma viruses. Interestingly, sequence analyses
on participants with early rebound revealed two patterns: 1) polyclonal VRC01-resistant
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viruses, and 2) monoclonal VRC01-resistant viruses. Further analyses on pre-cART
viruses showed that prevalent pre-existing VRC01 resistance was associated with
polyclonal rebound while varying pre-existing VRC01 resistance was associated with
monoclonal/oligoclonal rebound. This pattern of polyclonal rebound is similar to what is
observed in baseline ATI trials without additional intervention4,18,19, suggesting VRC01
exerted no selective pressure on viruses re-emerging from latency. In contrast, select
participants

with

variable

pre-cART

virus

susceptibility

to

VRC01

had

monoclonal/oligoclonal viral rebound, consistent with the recrudescence of a single,
clonally expanded virus. Phenotypic analyses of these monoclonal lineages revealed
increased resistance to VRC01 compared to pre-cART variants, suggesting VRC01 is
able to restrict the outgrowth of diverse HIV-1 variants emerging from the reservoir.
Finally, as expected, SGS on late rebounding Participants A02 (8 weeks) and A07 (11
weeks)

revealed

VRC01-sensitive

pre-cART

viruses

along

with

sensitive

monoclonal/oligoclonal rebound lineages. Together, these data suggest that SGS can
identify the effects of the in vivo selective pressure exerted by VRC01 through the
emergence

of

polyclonal

or

monoclonal/oligoclonal

rebound

lineages,

while

neutralization assays on these lineages can be used to further validate VRC01
sensitivities in vitro.

The finding that pre-existing resistance to VRC01 was common in the majority of
participants (9 of 11 participants) was surprising, since they had not been previously
exposed to VRC01. While autologous antibodies against the CD4 binding site (CD4bs)
of HIV-1 Env are common, potent broadly neutralizing CD4bs antibodies take years to
develop and the precise immunologic and virologic mechanisms guiding the evolution of
these antibodies in vivo is unclear20. Specific amino acid changes within the VRC01
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antibody-binding site, however, did reveal changes near or within the VRC01 epitope
(V5 and CD4-binding loop), suggesting VRC01 was applying specific selective pressure
on rebounding variants.

Env evolution and host immune responses during ATI
While other ATI studies have shown that first detectable rebound arises from multiple,
latently infected cells and establishes substantial diversity compared to HIV-1
transmission10,21, no data on the evolution of env under ATI conditions currently exists.
With access to longitudinal plasma samples from up to 47 weeks of viral rebound, we
had the unique opportunity to assess env evolution during ATI. These data provided an
important baseline assessment of viral rebound dynamics over multiple ATI time points.
Using SGS analyses, we find that maximum diversity rapidly increases over time (range
of 1.1% to 11.6% within 4 weeks of ATI), as multiple diverse viral lineages emerge and
early rebounding lineages evolve throughout the course of ATI. Phylogenetic analyses
of rebound diversity over time revealed two important findings: 1) select early lineages
were no longer sampled and therefore were probably cleared by later time points, and 2)
identical rebound viruses experience stochastic activation or evolve (persist). An
important caveat to these analyses is the limited sampling depth and potential
recombination events that may account for substantial population shifts. However, with
recent clinical data describing neutralization sieve-effects mediated by VRC013, I asked
whether host immune responses may also contribute to the evolution of the viral
quasispecies during the first weeks of rebound.
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Assessments of adaptive immunity during ATI in previously conducted clinical trials were
primarily focused on measures of T cell activation2 and viral rebound kinetics. Given that
the autologous antibody response takes six months or longer to develop strain-specific
neutralizing breadth against earlier viruses22–27, few studies have focused on the kinetics
of strain-specific neutralizing antibody responses arising during viral rebound.

I

hypothesized that autologous antibody responses generated during rebound will exert
selective pressure on neutralization-sensitive rebound variants, thus preventing
replication during subsequent ATI time points. To test this hypothesis, I developed Env
pseudotypes from persisting and cleared viral lineages and assessed neutralization
potency of autologous plasma from contemporaneous and longitudinal time points
through TZM-bl neutralization assays. I found that Env pseudotypes from cleared viral
lineages had a significant increase in sensitivity to autologous plasma compared to
persisting lineages by the second ATI time point (p=0.0286), suggesting a host-mediated
sieving effect on rebounding variants at early ATI time points. Furthermore, persisting
lineages were also found to have increased sensitivities to autologous plasma at later
ATI time points, suggesting that the neutralizing autologous antibody response against
early rebounding variants is dynamic and is able to evolve over time. The selective
pressure exerted by autologous neutralizing antibodies generated during rebound was
further supported in Chapter 4 of this thesis. Large, clonally expanded QVOA-derived
viruses that failed to expand during ATI were found to be more sensitive to autologous
antibodies generated during viral rebound than rebounding viruses. Interestingly, I also
found that QVOA-derived viruses maintained similar levels of resistance to VRC01. My
findings highlight the complex virus-host immune dynamics during ATI, and I conclude
that passively infused and host-derived neutralizing antibodies can provide strong
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selective pressure on viruses emerging from rebound, thereby influencing the evolution
of HIV in its host.

Safety of ATI
An important clinical finding in ACTG A5340 was that brief, closely monitored ATI with
VRC01 infusion was safe and well tolerated, and all participants were able to achieve
rapid viral suppression upon re-initiation of their original cART regimen. The effects of
ATI on the size and composition of the peripheral reservoir with transient viremia,
however, are unknown. In Chapter 4 of this thesis, I asked whether substantial changes
in the viral reservoir could be observed through quantitative and qualitative assessment
of latent reservoir viruses collected from pre-ATI and post-ATI (at least 6 months of
cART resuppression) time points. Levels of HIV-1 DNA, RNA, and infectious units per
million (IUPM) as determined by QVOA showed no significant within-person changes
between pre- and post-ATI resting CD4+ T cell samples, suggesting transient viremia
during rebound does not quantitatively affect the size of the viral reservoir.

Next, I

performed SGS on ex vivo-derived QVOA viruses from pre- and post-ATI time points.
These sequences were analyzed against rebound and pre-cART viruses from the same
participant in order to determine the phylogenetic relationship between PBMC and
plasma-derived viruses. Upon examination, I found that participants do not experience
substantial changes in the diversity of viruses found in the PBMC-derived latent
reservoir, nor were pre-ATI latent reservoir viruses able to accurately predict which
viruses would reactivate in vivo. These data suggest that in most participants, the
phylogenetic composition of virus populations induced from or directly sequenced from
resting CD4+ T cells are remarkably stable over a 9-12 month period between
samplings, despite transient viremia during brief ATI. Interestingly, I observed two
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exceptions to this pattern: in participants with low measures of the viral reservoir as
assessed by IUPM and HIV-DNA, as well as participants with narrow virus diversity
throughout pre-cART, rebound, and QVOA. Importantly, as curative strategies begin to
test therapeutic efficacy under prolonged periods of ATI and viral rebound, these
analyses will need to be reconsidered in the future.

Discordance between ex-vivo derived latent reservoir viruses and rebound
In addition to confirming that ATI did not substantially change the size or composition of
the reservoir in Chapter 4, in all participants with at least two latent viruses to assess,
large, clonally expanded viral lineages were found in the PBMC-derived latent reservoir
and were genetically distinct from pre-cART and rebound plasma viruses.

This

observation coincides with recently published clinical trials that have identified clonal
expansion within the peripheral viral reservoir28–30. In my analyses, I found that across
all participants, 68% of QVOA and 52% of proviral DNA viruses were clonal. Within
participants, I also found that the total percentage of identical sequences varied
(between 2% to 96%). However, even when the majority of pre-ATI latent reservoir
viruses display a single expanded clone, no members of this clonal population
reactivated in the two weeks of ATI. These findings reveal that the rebound viral
quasispecies is a minor variant within the viral reservoir that is not able to be sampled
through QVOA methods, thus preventing QVOA from accurately predicting viruses that
would reactivate during ATI in our studies.

We also observed noticeably different distributions of expanded clones in the QVOA and
intact genes of individual participant, further confirmed by GSI values and pairwise LD
analyses, suggesting our methods sampled distinct viral populations. When I compared
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sequences from rebound and latent viruses I observed striking discordance between the
two groups. This finding highlights that SGS analyses of HIV-1 env from QVOA and
proviral HIV-1 DNA is an inefficient method to predict the genotype of viruses that will
rebound, and that rebounding variants comprise only a small fraction of a potentially
large and diverse latent reservoir with the capacity to reactivate over time. Similarly, ex
vivo-stimulation of resting CD4 + T cells in QVOA assays represent a small fraction of
replication-competent

reservoir

viruses,

and

limiting

latent

cell

leukapheresis-derived peripheral cells further reduces sampling depth.

collection

to

While these

results show discordance between reservoir and rebound viruses, they also highlight the
complexity of the viral reservoir and the underlying factors that govern virus reactivation
and evolution during ATI. Future studies utilizing ATI methods should explore increasing
sampling depth to include latently infected cells in lymphoid tissue, single-cell integration
analyses to identify cellular regulators of expansion in vivo, and SGS analyses of
rebounding viruses from prolonged ATI periods to determine if clonally expanded cells
eventually reactivate over time. Additionally, current assays used to assess the diversity
of the latent reservoir ex vivo should consider that large, clonally expanded cells may
potentially confound viral diversity assessments with an extremely limited snapshot of
replication-competent viruses within the reservoir.

In conclusion
The virologic and immunologic dynamics of HIV-1 rebound can be elucidated through
SGS, molecular cloning of Env, and neutralization assays on plasma viruses, ex-vivo
activated QVOA viruses, and proviral DNA. Understanding which viruses emerge from
rebound, persist during subsequent rebound time points, and escape humoral immune
pressures can further inform mechanistic correlates of curative therapy efficacy. These
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studies also provide important information on the neutralization potency of the
autologous antibody response generated during ATI. While humoral immune responses
at rebound have not been shown to affect viral kinetics31,32, through these analyses I
found that neutralizing antibody responses at this point in time are strain-specific,
emerge shortly after viral rebound, and are able to exert significant pressure on select
viral lineages, preventing ongoing replication at subsequent ATI time points. Future
studies should consider building on these findings to determine whether neutralizing
antibodies can provide additive or synergistic selective pressure in combination with
curative therapies to suppress viral escape from genetically diverse viral variants
emerging from the viral reservoir during ATI.
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